NZ755082A - Production of novel beta-lactoglobulin preparations and related methods, uses, and food products - Google Patents
Production of novel beta-lactoglobulin preparations and related methods, uses, and food productsInfo
- Publication number
- NZ755082A NZ755082A NZ755082A NZ75508217A NZ755082A NZ 755082 A NZ755082 A NZ 755082A NZ 755082 A NZ755082 A NZ 755082A NZ 75508217 A NZ75508217 A NZ 75508217A NZ 755082 A NZ755082 A NZ 755082A
- Authority
- NZ
- New Zealand
- Prior art keywords
- blg
- protein
- whey protein
- composition
- whey
- Prior art date
Links
- 102000000119 Beta-lactoglobulin Human genes 0.000 title claims abstract description 933
- 108050008461 Beta-lactoglobulin Proteins 0.000 title claims abstract description 933
- 235000013305 food Nutrition 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims description 43
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 394
- 102000004169 proteins and genes Human genes 0.000 claims description 415
- 108090000623 proteins and genes Proteins 0.000 claims description 415
- 235000018102 proteins Nutrition 0.000 claims description 401
- 235000021119 whey protein Nutrition 0.000 claims description 387
- 102000007544 Whey Proteins Human genes 0.000 claims description 376
- 108010046377 Whey Proteins Proteins 0.000 claims description 376
- 239000012460 protein solution Substances 0.000 claims description 248
- 230000005712 crystallization Effects 0.000 claims description 106
- 238000002425 crystallisation Methods 0.000 claims description 105
- 239000000843 powder Substances 0.000 claims description 105
- 239000007787 solid Substances 0.000 claims description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 92
- 239000007788 liquid Substances 0.000 claims description 85
- 239000005862 Whey Substances 0.000 claims description 68
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 58
- 239000011574 phosphorus Substances 0.000 claims description 58
- 229910052698 phosphorus Inorganic materials 0.000 claims description 58
- 238000005406 washing Methods 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 50
- 238000001035 drying Methods 0.000 claims description 48
- 239000012466 permeate Substances 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 31
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 26
- 239000011707 mineral Substances 0.000 claims description 26
- 239000012141 concentrate Substances 0.000 claims description 23
- 238000001953 recrystallisation Methods 0.000 claims description 23
- 235000013361 beverage Nutrition 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 20
- 238000007792 addition Methods 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 17
- 235000009508 confectionery Nutrition 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 235000012041 food component Nutrition 0.000 claims description 8
- 239000005417 food ingredient Substances 0.000 claims description 8
- 235000007983 food acid Nutrition 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 75
- 102100016653 LALBA Human genes 0.000 description 54
- 101700017573 LALBA Proteins 0.000 description 54
- 235000014786 phosphorus Nutrition 0.000 description 54
- 235000021241 α-lactalbumin Nutrition 0.000 description 54
- 150000002500 ions Chemical class 0.000 description 41
- 239000012465 retentate Substances 0.000 description 34
- 239000002002 slurry Substances 0.000 description 32
- 239000012065 filter cake Substances 0.000 description 29
- 230000036425 denaturation Effects 0.000 description 28
- 238000004925 denaturation Methods 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 108010067454 caseinomacropeptide Proteins 0.000 description 26
- 239000012452 mother liquor Substances 0.000 description 26
- 235000010755 mineral Nutrition 0.000 description 25
- 239000011148 porous material Substances 0.000 description 23
- 235000008504 concentrate Nutrition 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 239000011734 sodium Substances 0.000 description 21
- 239000011575 calcium Substances 0.000 description 20
- 238000011026 diafiltration Methods 0.000 description 19
- 239000011777 magnesium Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 238000000926 separation method Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 235000014633 carbohydrates Nutrition 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229910052791 calcium Inorganic materials 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 229910052700 potassium Inorganic materials 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- 108010076119 Caseins Proteins 0.000 description 12
- 210000004080 Milk Anatomy 0.000 description 12
- 239000005018 casein Substances 0.000 description 12
- 235000021240 caseins Nutrition 0.000 description 12
- 235000013336 milk Nutrition 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 230000002829 reduced Effects 0.000 description 12
- 238000000108 ultra-filtration Methods 0.000 description 12
- 210000002966 Serum Anatomy 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 235000012970 cakes Nutrition 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000024188 Andala Species 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000002269 spontaneous Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000001223 reverse osmosis Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000001083 Kidney Disease Diseases 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 239000002535 acidifier Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000001143 conditioned Effects 0.000 description 4
- 238000009295 crossflow filtration Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 108010070158 EC 2.4.1.22 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000002730 additional Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 229920001940 conductive polymer Polymers 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000005429 turbidity Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940078795 Lactoferrin Drugs 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052925 anhydrite Inorganic materials 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 238000000120 microwave digestion Methods 0.000 description 2
- 108010071421 milk fat globule Proteins 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000020825 overweight Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- CBQYNPHHHJTCJS-UHFFFAOYSA-N Alline Chemical compound C1=CC=C2C3(O)CCN(C)C3NC2=C1 CBQYNPHHHJTCJS-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102100019639 B4GALT1 Human genes 0.000 description 1
- 101710025565 B4GALT1 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 235000019749 Dry matter Nutrition 0.000 description 1
- 101700043311 GGTA1 Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000019298 Lipocalins Human genes 0.000 description 1
- 108050006654 Lipocalins Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 240000002546 Prunus mume Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000001427 coherent Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000002572 peristaltic Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003247 radioactive fallout Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 101700008740 vif Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to a new method of producing isolated beta-lactoglobulin compositions and/or compositions containing crystallised beta-lactoglobulin. The invention furthermore relates to new beta-lactoglobulin compositions, uses of these compositions and food products comprising these compositions. compositions.
Description
WO 15520
PRODUCTION OF NOVEL BETA-LACTOGLOBULIN PREPARATIONS AND D METHODS,
USES, AND FOOD PRODUCTS
FIELD OF THE INVENTION
The present invention relates to a new method of producing ed beta—lactoglobulin compo—
sitions and/or compositions containing crystallised beta—lactoglobulin. The invention further—
more relates to new actoglobulin compositions, uses of these compositions and food
products comprising these compositions.
BACKGROUND OF THE INVENTION
The concept of milk n fractionation is well-known in the art and has been developed dur—
ing the last decades to an array of technologies for preparing compositions enriched with vari—
ous milk protein species each having specific properties and characteristics.
Isolation of beta—lactoglobulin (BLG) from milk serum or whey is the subject of a number of
publications and typically involves multiple separation steps and often chromatographic tech—
niques to arrive at a purified beta—lactoglobulin product.
For example, de Jongh et a/ (Mild ion Procedure Discloses New Protein Structural Proper—
ties of B—Lactoglobulin, J Dairy Sci., vol. 84(3), 2001, pages 562-571) described purification of
BLG from freshly milked milk by low temperature acid coagulation of casein and by subjecting
the obtained acid whey to a combination of affinity chromatography (DEAE Sepharose) and gel
permeation chromatography. The obtained BLG composition was stated to contain 0.985 g be—
toglobulin per 1 g protein.
Slack et al (Journal of Food Processing and Preservation, vol. 10, 1986, pages 19—30) explored
a ent ch and prepared riched precipitates by pH adjusting demineralised acid
whey and sweet whey to pH 4.65 and ting the formed precipitate by centrifugation and
decantation. The obtained precipitate pellets were described as being relatively insoluble and
contained a significant amount of protein impurities in additional BLG. No crystal formation was
observed. It should be noted that the BLG precipitates that may form at pH 4.65 are not BLG
crystals.
W0 2018!115520
Palmer alline Globulin from Cow's Milk, J. Biol. Chem., Vol. 104, 1934, pages 359—372)
reported a laborious and time consuming process for producing protein crystals based on acid
whey using several sequences of salt precipitation of unwanted proteins, pH—adjustments and
is to remove other unwanted proteins. Finally, when a highly purified BLG solution had
been obtained, BLG was crystallized. The process lasted more than 12 days and required addi—
tion of toluene. The procedures disclosed in Palmer are therefore incompatible with safe food
production and provides products that are clearly not edible.
Aschaffenburg et al (Improved Method for the ation of Crystalline beta—Lactoglobulin
and alpha—Lactalbumin from Cow's Milk, Bioch., vol. 65, 1957, pages 273—277) discloses an
ed process relative to the process of Palmer’s process, which improvement allows for
preparation of beta—lactoglobulin crystals in the order of few days instead of weeks. However,
the improved method still requires l of unwanted proteins prior to crystallisation and
rmore employs toluene for the crystallisation, which makes it incompatible with safe food
production.
JP H10 218755 A discloses tion of cosmetic compositions containing a melanin—producing
inhibitor which comprises BLG as an active ingredient. The document furthermore suggests that
BLG e.g. may be isolated by the following process: Hydrochloric acid is added to milk to precipi—
tate casein followed by filtration to obtain whey. The pH of the whey is ed to 6.0 and
ammonium e is added in an amount of half saturation; the precipitated protein is removed
by salting out, and a filtrate is recovered. The filtrate is saturated with ammonium sulfate and
the precipitated protein is recovered. The recovered protein is again dissolved in water and dia—
lyzed at pH 5.2 to separate the crystals, and B—lactoglobulin is prepared at a proportion of
about 1.8 g from 1 L whey. However, the general process steps of the proposed s de—
d in JP H10 218755 A are insufficient to lead to the formation of BLG crystals. The docu—
ment therefore does not contain an enabling disclosure of crystallisation of BLG or of BLG crys—
tals.
3O US 2 790 790 discloses a process for itation of proteins from solution, and more u—
larly to the fractional precipitation of relatively unconjugated proteins from s solution by
the use of sodium chloride as the precipitant. The process is suggested to be useful for isolating
BLG by NaCl-induced precipitation at pH 8. In example II of the document it is suggested
that the NaCl—precipitate may be dialysed in the usual manner to form crystalline B—
lactoglobulin. However, US 2 790 790 does not demonstrate that formation of BLG crystals at
pH 3.6—3.8 is actually possible and contains no reference to meaning of “the usual manner” of
dialyzing a BLG precipitate. The document therefore does not contain an enabling sure of
crystallisation of BLG or of BLG crystals.
W0 2018!115520
SUMMARY OF THE INVENTION
By accident, the present inventors made the sing discovery that highly pure BLG crystals
may be ed directly in crude whey protein solution which contains significant amounts of
other whey proteins in addition to BLG and without the use of organic solvents such as toluene.
This is contrary to the common general knowledge in the art which teaches that proteins have
to be highly purified before one can hope to crystallise them, and not all proteins can be crys—
tallised.
This discovery has the potential to change the way whey protein is d and fractionated in
the dairy ry and opens up for both efficient and gentle production of highly purified BLG
which is safe to use as a food ingredient.
Thus, an aspect of the invention pertains to a method of preparing an edible composition com—
prising beta—lactoglobulin (BLG) in llised and/or ed form, the method comprising the
steps of
a) providing a whey protein solution comprising BLG and at least one additional whey protein,
said whey protein solution is supersaturated with respect to BLG and has a pH in the range of
—6,
b) crystallising BLG in the supersaturated whey protein solution, and
c) optionally, separating BLG crystals from the remaining whey protein solution.
The present inventors have furthermore found that edible whey protein compositions in powder
form that contain BLG ls have significantly higher bulk ies than comparable compo—
sitions of the prior art. This is advantageous as it eases the handling of the powder and makes
it less dusty.
Thus, another aspect of the invention pertains to an edible composition comprising beta—
lactoglobulin in llised and/or isolated form, e.g. obtainable by one or more methods de-
scribed herein. The edible composition may e.g. be a powder containing BLG crystals and hav—
ing a bulk density of at least 0.40 g/mL. Alternatively, the edible composition may be a liquid
suspension or slurry containing BLG crystals.
In the context of the present invention, a dry product such as e.g. a powder, which comprises
“BLG crystals” contains the t obtained from drying a suspension of BLG crystals and the
WO 15520
crystal structure of the wet BLG crystals may have been distorted during the drying process and
may at least partially have lost their x—ray diffraction characteristics. Along the same lines, the
terms “dry BLG crystal” and “dried BLG crystal" refer to the particle obtained from drying a wet
BLG l and this dry particle need not have a crystal structure itself. However, the present
inventors have observed that when dried BLG crystals are resuspended in cold (4 degrees C)
demineralised water in the weight ratio 2 part water to 1 part dried BLG crystals the BLG crystal
are rehydrated and resume substantially the same crystal structure (space type and unit
cell dimension) as before drying.
BLG is well-known to be a great source of essential amino acids, including e.g. leucine, and the
edible BLG composition provided by the present invention therefore has several interesting nu-
tritional uses.
An additional aspect of the invention pertains to an isolated BLG crystal having an hombic
space group P 21 21 21 and the unit cell dimensions a=68.68 (:l:5%) A, b = 68.68 (15%) A, and
c = 156.65 (i5%) IX; and wherein the crystal has the unit cell integral angles o=90°, B=90°,
and v=90°.
Yet an aspect of the invention pertains to the use of the edible composition as defined herein as
a food ingredient.
A further aspect of the invention pertains to a food product comprising the edible ition
as defined herein and a fat source and/or a carbohydrate source.
BRIEF DESCRIPTION OF THE S
Figure 1 shows two overlaid tograms of a crude whey protein solution (solid line) based
on sweet whey and the resulting mother liquor after crystallisation (dashed line). The difference
n the solid and the dashed lines is due to removed BLG crystals.
Figure 2 is a cope photo of the BLG crystals recovered from Example 1.
Figure 3 is a chromatogram of recovered BLG crystal from Example 1.
Figure 4 is a plot of the relation n the conductivity of the whey protein solution and the
obtained yield of recovered BLG crystals.
RECTIFIED SHEET (RULE 91) ISA/EP
W0 2018!115520 2017/084553
Figure 5 is a plot of the relationship between temperature and conductivity of the whey protein
solution and the ed yield of recovered BLG crystals.
Figure 6 illustrates the relationship between the total protein content (shown indirectly by de—
grees Brix which is proportional with the protein content) of the whey protein solution and the
obtained yield of recovered BLG ls.
Figure 7 shows chromatograms of feed 1 of Example 3 (solid line) and the mother liquor
(dashed line) obtained after crystallisation and removal of BLG crystals.
Figure 8 is a cope photo of a sample taken during the early stages of the crystallization
of feed 1 of Example 3.
Figure 9 is a microscope photo of a sample taken after completion of the crystallization of feed
1 of Example 3.
Figure 10 shows the chromatogram of washed BLG crystals obtained from feed 1 of Example 3.
Figure 11 shows chromatograms of feed 2 of e 3 (solid line) and the mother liquor
(dashed line) obtained after crystallisation and removal of BLG ls.
Figure 12 shows a picture of feed 2 of Example 3 before (left—hand e) and after (right—
hand picture) crystallization.
Figure 13 shows a microscope photo of the BLG cwstals, both whole and fragmented, obtained
from feed 2 of Example 3.
Figure 14 and 15 show that raising the conductivity or altering the pH of a BLG crystal slurry
causes the BLG crystals to ve.
Figure 17 shows picture of feed 3 of Example 3 before (left—hand picture) and after (right-hand
picture) crystallization.
Figure 18 is a microscope photo of the BLG crystals recovered from feed 3 of Example 3.
Figure 19 shows a chromatogram of the recovered BLG crystal of feed 3 of Example 3 without
any washing step.
Figure 20 shows the impact of increasing conductivity on the yield of recovered BLG crystals.
W0 2018!115520
Figure 21 is a microscope photo of BLG crystals formed at a conductivity of 4.20 mS/cm.
Figure 22 shows a microscope photo of BLG crystals from the early stages of the crystallization
of an SPC—based whey protein solution.
Figure 23 illustrates the difference in bulk density of a standard whey protein isolate (WPI) and
a high purity BLG composition of the invention, which composition contains BLG crystals.
Figure 24 is a photo of a spin filter in which BLG crystals of Example 3, feed 1, have been sepa—
rated from the mother liquid.
Figure 25 is a photo of sub—samples of the six low phosphorous beverage samples of Example
8. From left to right the sub—samples are sample A, B, C, D, E, and F.
Figure 26 is a schematic illustration of the crystallisation process variant of Example 10 which
uses DCF for separation BLG ls from the mother liquor.
Figure 27 shows three photos of the filter cake obtained from separating BLG crystal and moth-
er liquor using a filter centrifuge.
DETAILED DESCRIPTION
As mentioned above, an aspect of the invention pertains to a method of preparing an edible
composition comprising actoglobulin (BLG) in crystallised and/or isolated form, the meth—
od comprising the steps of
a) providing a whey protein solution comprising BLG and at least one additional whey pro—
tein, said whey protein solution is supersaturated with t to BLG and has a pH in the
range of 5—6,
b) crystallising BLG in the supersaturated whey protein on, and
c) optionally, separating BLG crystals from the remaining whey protein on.
In the context of the present invention, the term “edible composition” pertains to a ition
that is safe for human consumption and use as a food ingredient and that does not contain
problematic amounts of toxic components such as toluene or other unwanted c ts.
BLG is the most predominant protein in bovine whey and milk serum and exists in several ge—
netic ts, the main ones in cow milk being labelled A and B. BLG is a lipocalin protein, and
W0 2018!115520
can bind many hydrophobic les, suggesting a role in their transport. BLG has also been
shown to be able to bind iron via siderophores and might have a role in combating pathogens. A
homologue of BLG is lacking in human breast milk.
Bovine BLG is a relatively small protein of approx. 162 amino acid residues with a molecular
weight of approx. 18.3—18.4 kDa. Under logical conditions it is predominantly dimeric, but
dissociates to a monomer below about pH 3, preserving its native state as determined using
NMR. Conversely, BLG also occurs in tetrameric, octameric and other multimeric ation
forms under a variety of l conditions.
BLG solutions can form gels under various conditions, when the native structure is sufficiently
destabilised to allow aggregation. Under prolonged heating at low pH and low ionic strength, a
transparent ‘fine—stranded' gel is formed in which the n molecules assemble into long stiff
fibres.
In the context of the present invention, the term “BLG” or “beta-Iactoglobulin” pertains to BLG
from mammal species, e.g. in native and/or glycosylated forms and includes the naturally oc—
curring genetic variants.
In the context of the present invention, the term “crysta I" pertains to a solid material whose
constituents (such as atoms, molecules or ions) are arranged in a highly ordered microscopic
ure, forming a crystal lattice that extends in all directions. BLG crystals are protein crys—
tals that primarily contains BLG arranged in a highly ordered copic structure, forming a
crystal lattice that extends in all directions. The BLG crystals may e.g. be monolithic or poly—
lline and may e.g. be intact crystals, fragments of crystals, or a combination thereof.
Fragments of crystal are e.g. formed when intact crystals are subjected to ical shear
during processing. Fragments of crystals also have the highly ordered copic structure of
l but may lack the even surface and/or even edges or corners of an intact crystal. See
e.g. Figure 18 for an example of many intact BLG crystals and Figure 13 for an example of
fragments of BLG crystals. In both cases the BLG crystal or l fragments can be fied
visually as well—defined, compact and coherent ures using light microscopy. BLG crystal or
crystal fragments are often at least partially transparent. Protein crystals are furthermore
known to be birefringent and this optical property can be used to identify unknown particles as
having crystal structure. Non—crystalline BLG aggregates, on the other hand, appear as poorly
defined, non—transparent, and as open or porous lumps of irregular size.
In the t of the present invention, the term “crystallise” pertains to formation of protein
crystals. Crystallisation may e.g. happen spontaneously or be initiated by the addition of crys—
tallisation seeds.
W0 2018!115520
The edible composition comprises BLG in crystallised and/or isolated form. An edible composi—
tion that comprises BLG in isolated form comprises at least 80% (w/w) BLG relative to total
solids. An edible composition that comprises BLG in crystallised form comprises at least some
BLG crystals, and preferably a significant amount of BLG crystals.
BLG crystals can often be observed by microscopy and may even reach a size which makes
them visible by eye.
In the context of the present invention, a liquid which is “supersaturated” or “supersaturated
with respect to BLG” contains a concentration of dissolved BLG which is above the saturation
point of BLG in that liquid at the given physical and chemical ions. The term “supersatu—
rated” is well—known in the field of crystallisation (see e.g. Gérard Coquerela, ”Crystallization of
molecular systems from solution: phase diagrams, supersaturation and other basic concepts”,
Chemical Society Reviews, p. 2286—2300, Issue 7, 2014) and supersaturation can be deter—
mined by a number of different measurement ques (e.g. by spectroscopy or particle size
analysis). In the t of the present invention, supersaturation with respect to BLG is de—
termined by the following procedure.
Procedure for testing whether a liguid at a specific set of conditions is supersaturated with re—
spect to BLG:
a) Transfer a 50 ml sample of the liquid to be tested to a centrifuge tube (VWR Catalogue no.
02) having a height of 115 mm, an inside diameter of 25 mm and a capacity of 50 mL.
Care should be taken to keep the sample and subsequent fractions thereof at the original physi—
cal and chemical conditions of the liquid during steps a) — h).
b) The sample is ately centrifuged at 3000 g for 3.0 minutes with max. 30 s ac—
celeration and max 30 seconds deceleration.
c) Immediately after the centrifugation, transfer as much as possible of the supernatant (with—
out bing the pellet if a pellet has formed) to a second fuge tube (same type as in
3O step a)
d) Take a 0.05 mL subsample of the supernatant (subsample A)
e) Add 10 mg BLG crystals (at least 98% pure BLG relative to total solids) having a particle size
of at most 200 micron to a second fuge tube and e the mixture.
f) Allow the second centrifuge tube to stand for 60 minutes at the original temperature.
9) Immediately after step f), centrifuge the second centrifuge tube at 500 g for 10 s and
then take r 0.05 mL ple of the supernatant (subsample B).
h) Recover the centrifugation pellet of step 9) if there is one, resuspend it in miIIiQ water and
immediately inspect the suspension for presence of crystals that are visible by microscopy.
W0 2018!115520
i) Determine the concentration of BLG in subsamples A and B using the method outlined in EX—
ample 9.9 — the results are expressed as % BLG w/w relative to the total weight of the sub—
samples. The concentration of BLG of subsample A is referred to as CBLG,A and the concentra—
tion of BLG of ple B is referred to as CBLG, B.
j) The liquid from which the sample of step a) was taken was supersaturated (at the specific
conditions) if cBLG, B is lower than cBLG,A and if crystals are observed in step i).
In the context of the present ion, the terms d” and “solution” encompass composi—
tions that contain a ation of liquid and solid or semi—solid particles such as e.g. protein
crystals or other protein particles. A “liquid” or a “solution” may therefore be a suspension or
even a slurry. However, a “liquid” and “solution” is preferably pumpable.
In some preferred embodiments of the ion, the method does not contain the separation
of step c) and provides an edible composition which comprises both BLG crystals and the addi-
tional whey protein. If this method variant rmore include the drying of step f) it provides
a dry composition containing BLG crystals and the additional whey protein, Le. a WPC or WPI in
which at least a n of the BLG is present in the form of BLG ls. Preferably, the meth—
od contains the steps a), b) and f) in direct sequence.
If the whey protein feed is a whey protein concentrate (WPC), a whey protein isolate (WPI), a
serum protein concentrate (SPC) or a serum protein isolate (SPI), the above method variant
makes it possible to prepare a WPC, WPI, SPC, or SPI in liquid or dry form, in which at least a
portion of the BLG is in crystal form.
The terms “whey protein concentrate” and “serum protein concentration” pertains to dry or
aqueous compositions in which ns a total amount of protein of 20—89% (w/w) relative to
total solids.
A WPC or an SPC preferably contains:
3O 20—89% (w/w) protein relative to total solids,
—70% (w/w) BLG relative to total protein,
8—50% (w/w) ALA ve to total protein, and
0-40% (w/w) CMP relative to protein.
Alternatively, but also preferred, a WPC or an SPC may contain:
—89% (w/w) protein ve to total solids,
-90% (w/w) BLG relative to total protein,
4—50% (w/w) ALA relative to total protein, and
0—40% (w/w) CMP relative to protein.
W0 2018l115520 2017/084553
Preferably, a WPC or an SPC contains:
—89% (w/w) protein relative to total ,
—80% (w/w) BLG relative to total protein,
4—50% (w/w) ALA relative to total protein, and
0—40% (w/w) CMP relative to protein.
More preferably a WPC or a SPC contains:
70—89% (w/w) n relative to total ,
—90% (w/w) BLG relative to total protein,
4—35°/o (w/w) ALA relative to total protein, and
0—25% (w/w) CMP relative to protein.
The terms “whey protein isolate” and “serum protein isolate” pertains to dry or aqueous compo—
sitions in which contain a total amount of n of 90—100% (w/w) relative to total solids.
A WPI or a SPI preferably contains:
90—100% (w/w) protein relative to total ,
15-70% (w/w) BLG relative to total protein,
8—50% (w/w) ALA relative to total protein, and
0—40% (w/w) CMP relative to total protein.
atively, but also preferred, a WPI or a SPI may contain:
90—100% (w/w) protein relative to total solids,
—95% (w/w) BLG relative to total protein,
4—35% (w/w) ALA relative to total protein, and
0—25% (w/w) CMP relative to total protein.
3O More preferably a WPI or a SPI may contain:
90—100°/o (w/w) protein relative to total solids,
—90% (w/w) BLG relative to total protein,
4-35% (w/w) ALA relative to total protein, and
0—25% (w/w) CMP relative to total protein.
In some preferred embodiments of the invention, the method furthermore comprises a step d)
of washing BLG crystals, e.g. the separated BLG crystals obtained from step c).
W0 2018!115520
In some preferred embodiments of the invention, the method furthermore comprises a step e)
of re-crystallising BLG crystals, e.g. the BLG crystals obtained from step c) or d).
The method may e.g. comprise, or even consist of, steps a), b), c), d), and e). Alternatively,
the method may comprise, or even consist, of steps a), b), c), and e).
In some particularly preferred embodiments of the invention, the method furthermore compris—
es a step f) of drying a ntaining composition derived from step b), c), d), or e).
The method may for example comprise, or even consist of, steps a), b), and f).
Alternatively, the method may comprise, or even consist of, steps a), b), c) and f).
Alternatively, the method may comprise, or even consist of, steps a), b), c), d) and f).
Alternatively, the method may comprise, or even consist of, steps a), b), c), d), e) and f).
As said, step a) of the present invention es providing a whey protein solution which com—
prises BLG and at least an additional whey protein.
In the context of the present invention, the term “whey protein” pertains to protein that is
found in whey or in milk serum. The whey protein of the whey protein on may be a subset
of the protein species found in whey or milk serum or it may be the complete set of protein
species found in whey or/and in milk serum. However, the whey protein solution always con—
tains BLG.
In the context of the present invention, the term “additional protein” means a protein that is
not BLG. The additional protein that is present in the whey protein solution typically comprises
one or more of the non—BLG ns that are found in milk serum or whey. Non—limiting exam—
ples of such proteins are alpha—lactalbumin, bovine serum albumin, immunoglobulines, o—
macropeptide (CMP), ontin, lactoferrin, and milk fat globule membrane proteins.
3O The whey n solution may therefore preferably contain at least one additional whey protein
selected from the group ting of lactalbumin, bovine serum n, globu—
lines, caseinomacropeptide (CMP), osteopontin, lactoferrin, milk fat globule membrane proteins,
and combinations thereof.
Alpha—lactalbumin (ALA) is a protein present in the milk of almost all mammalian species. ALA
forms the regulatory subunit of the lactose synthase (LS) heterodimer and B—1,4—
galactosyltransferase (beta4Gal—T1) forms the tic component. Together, these proteins
enable LS to produce lactose by transferring galactose moieties to glucose. As a multimer, al—
pha-lactalbumin strongly binds m and zinc ions and may possess bactericidal or antitumor
W0 2018!115520
activity. One of the main structural differences with beta-lactoglobulin is that ALA does not have
any free thiol group that can serve as the starting—point for a covalent aggregation reaction. As
a result, pure ALA will not form gels upon denaturation and acidification.
In the context of the present invention, the term “ALA” or “alpha—lactalbumin” pertains to al—
ctalbumin from mammal species, e.g. in native and/or glycosylated forms and includes
the naturally occurring genetic variants.
In some embodiments of the invention, the whey protein solution comprises at most 10%
(w/w) casein relative to the total amount of protein, preferably at most 5%(w/w), more pre—
ferred at most 1% (w/w), and even more preferred at most 0.5% casein ve to the total
amount of n. In some preferred embodiments of the invention, the whey protein solution
does not contain any detectable amount of .
The term “milk serum” pertains to the liquid which remains when casein and milk fat globules
have been removed from milk, e.g. by microfiltration or large pore ultrafiltration. Milk serum
may also be referred to as “ideal whey”.
The term “milk serum protein” or “serum protein” pertains to the protein which is present in the
milk serum.
The term “whey” pertains to the liquid supernatant that is left after the casein of milk has been
precipitated and d. Casein precipitation may e.g. be accomplished by ication of
milk and/or by use of rennet enzyme.
Several types of whey exist, such as “sweet whey", which is the whey product ed by
rennet—based itation of casein, and “acid whey” or “sour whey” which is the whey product
produced by acid—based precipitation of casein. Acid—based precipitation of casein may e.g. be
accomplished by addition of food acids or by means of bacterial cultures.
In some preferred embodiments of the invention, the whey protein on of step a) compris—
es at least 5% (w/w) additional whey protein relative to the total amount of protein. Preferably,
the whey protein solution of step a) comprises at least 10% (w/w) additional whey protein rela-
tive to the total amount of n. More preferably, the whey protein solution of step a) com—
prises at least 15% (w/w) additional whey protein relative to the total amount of protein.
Even more preferably, the whey protein solution of step a) comprises at least 20% (w/w) addi—
tional whey protein relative to the total amount of protein. Most ably, the whey protein
solution of step a) may comprise at least 30% (w/w) additional whey protein ve to the
total amount of protein.
W0 2018!115520
In other preferred ments of the invention, the whey protein solution of step a) compris—
es at least 1% (w/w) additional whey protein relative to the total amount of protein. Preferably,
the whey protein solution of step a) comprises at least 2% (w/w) additional whey protein rela—
tive to the total amount of protein. Even more preferably, the whey protein solution of step a)
comprises at least 3% (w/w) additional whey protein relative to the total amount of protein.
Most ably, the whey protein solution of step a) may comprise at least 4% (w/w) addition—
al whey protein relative to the total amount of protein.
In yet other preferred embodiments of the invention, the whey protein solution of step a) com—
prises at least 35% (w/w) additional whey n relative to the total amount of protein. Pref—
erably, the whey protein solution of step a) may comprise at least 40% (w/w) additional whey
n ve to the total amount of protein. More preferably, the whey protein solution of
step a) may e.g. comprise at least 45% (w/w) additional whey protein relative to the total
amount of n. Even more preferably, the whey protein solution of step a) may comprise at
least 50% (w/w) additional whey protein relative to the total amount of protein.
In some preferred embodiments of the invention the whey protein solution of step a) comprises
in the range of 5—90% (w/w) additional whey protein relative to the total amount of protein.
Preferably, the whey protein solution of step a) may comprise in the range of 10-80% (w/w)
additional whey n relative to the total amount of protein. The whey protein solution of
step a) may e.g. comprise in the range of 20—70% (w/w) additional whey protein relative to the
total amount of protein. Preferably, the whey n solution of step a) comprises in the range
of 30—70% (w/w) additional whey protein relative to the total amount of protein.
As said, the present inventors have found that it is possible to crystallize BLG without the use of
organic solvents. This purification approach can also be used to refine preparations containing
whey n, which preparations have already been subjected to some BLG purification and
provides simple methods of increasing the purity of BLG even further. Thus, in some preferred
3O embodiments of the invention the whey protein solution of step a) comprises in the range of 1—
% (w/w) additional whey protein ve to the total amount of n. Preferably, the whey
protein solution of step a) may comprise in the range of 2—15% (w/w) additional whey n
relative to the total amount of n. Even more preferably, the whey protein solution of step
a) may e.g. comprise in the range of 3—10% (w/w) additional whey protein relative to the total
amount of protein.
In some embodiments of the ion the whey protein solution of step a) comprises at least
% (w/w) ALA relative to the total amount of protein. Preferably, the whey protein solution of
step a) comprises at least 10% (w/w) ALA ve to the total amount of protein. Even more
W0 2018!115520
preferably, the whey protein solution of step a) comprises at least 15% (w/w) ALA relative to
the total amount of protein. Alternatively, the whey protein solution of step a) may comprise at
least 20% (w/w) ALA relative to the total amount of protein.
In some preferred embodiments of the invention the whey protein solution of step a) comprises
at least 25% (w/w) ALA relative to the total amount of protein. Preferably, the whey protein
solution of step a) comprises at least 30% (w/w) ALA relative to the total amount of n.
The whey protein on of step a) preferably comprises at least 35% (w/w) ALA relative to
the total amount of protein. Even more ably, the whey protein solution of step a) may
comprise at least 40% (w/w) ALA relative to the total amount of protein.
In some preferred embodiments of the ion the whey protein solution of step a) comprises
in the range of 5—95% (w/w) ALA relative to the total amount of protein. Preferably, the whey
protein solution of step a) comprises in the range of 5-70% (w/w) ALA relative to the total
amount of protein. Even more preferably, the whey protein solution of step a) may comprise in
the range of 10—60% (w/w) ALA relative to the total amount of protein. The whey protein solu-
tion of step a) preferably comprises in the range of 12—50% (w/w) ALA relative to the total
amount of protein. Even more preferred, the whey protein solution of step a) may comprise in
the range of 20—45% (w/w) ALA ve to the total amount of protein.
In some preferred embodiments of the invention the whey protein solution of step a) has a
weight ratio between BLG and ALA of at least 0.01. Preferably, the whey n solution of step
a) has a weight ratio between BLG and ALA of at least 0.5. Even more preferably, the whey
protein solution of step a) has a weight ratio between BLG and ALA of at least 1, such as e.g. at
least 2. For example, the whey protein solution of step a) may have a weight ratio between BLG
and ALA of at least 3.
Amounts and concentrations of BLG and other proteins in the whey protein on and the
whey protein feed all refer to dissolved protein and do not include precipitated or crystallised
protein.
In the context of the present invention, the term t ratio” between component X and
component Y means the value obtained by the calculation mX/mY n mX is the amount
t) of components X and my is the amount (weight) of components Y.
In some preferred embodiments of the ion the whey n solution of step a) has a
weight ratio between BLG and ALA in the range of 001—20. Preferably, the whey protein solu—
tion of step a) has a weight ratio between BLG and ALA in the range of 02—10. Even more pref-
erably, the whey protein solution of step a) has a weight ratio between BLG and ALA in the
W0 2018!115520
range of 0.5—4. For example, the whey protein solution of step a) may have a weight ratio be—
tween BLG and ALA in the range of 1—3.
In some preferred embodiments of the invention the whey protein on of step a) comprises
at least 1% (w/w) BLG relative to the total amount of protein. Preferably, the whey protein so—
lution of step a) comprises at least 2% (w/w) BLG relative to the total amount of protein. Even
more ably, the whey protein solution of step a) comprises at least 5% (w/w) BLG relative
to the total amount of protein. Preferably, the whey protein solution of step a) may comprise at
least 10% (w/w) BLG relative to the total amount of protein.
In some red embodiments of the invention the whey protein solution of step a) comprises
at least 12% (w/w) BLG relative to the total amount of protein. For example, the whey protein
solution of step a) may comprise at least 15% (w/w) BLG relative to the total amount of pro—
tein. The whey protein solution of step a) may e.g. comprise at least 20% (w/w) BLG relative to
the total amount of protein. Alternatively, the whey protein solution of step a) may comprise at
least 30% (w/w) BLG relative to the total amount of protein.
In some particularly preferred embodiments of the invention the whey n solution of step
a) ses at most 95% (w/w) BLG relative to the total amount of protein. Preferably, the
whey protein solution of step a) may comprise at most 90% (w/w) BLG relative to the total
amount of protein. More preferably, the whey protein solution of step a) may e.g. comprise at
most 85% (w/w) BLG relative to the total amount of protein. Even more preferably, the whey
protein solution of step a) may e.g. comprise at most 80% (w/w) BLG relative to the total
amount of protein. Preferably, the whey n on of step a) may comprise at most 78%
(w/w) BLG relative to the total amount of protein. ably, the whey protein solution of step
a) may comprise at most 75% (w/w) BLG relative to the total amount of protein.
In some preferred embodiments of the invention the whey protein solution of step a) comprises
in the range of 1—95% (w/w) BLG ve to the total amount of protein. Preferably, the whey
3O protein solution of step a) may comprise in the range of 5—90% (w/w) BLG relative to the total
amount of protein. More preferably the whey protein solution of step a) comprises in the range
of 10—85% (w/w) BLG relative to the total amount of n. Even more ably the whey
protein solution of step a) ses in the range of 10-80% (w/w) BLG relative to the total
amount of protein. Most preferably, the whey n solution of step a) may comprise in the
range of 20—70% (w/w) BLG relative to the total amount of protein.
In other preferred embodiments of the invention the whey protein solution of step a) comprises
in the range of 10—95% (w/w) BLG relative to the total amount of protein. Preferably, the whey
protein solution of step a) may comprise in the range of 12—90% (w/w) BLG relative to the total
W0 2018!115520
amount of protein. More preferably the whey protein on of step a) ses in the range
of 15—85% (w/w) BLG relative to the total amount of protein. Even more ably the whey
protein solution of step a) comprises in the range of 15—80% (w/w) BLG relative to the total
amount of protein. Most preferably, the whey protein solution of step a) may comprise in the
range of 30-70% (w/w) BLG relative to the total amount of protein.
In some preferred embodiments of the invention the whey protein on of step a) comprises
at least 0.4% (w/w) BLG relative to the weight of the whey protein solution. Preferably the
whey protein solution ses at least 1.0% (w/w) BLG. More preferably the whey protein
solution comprises at least 2.0% (w/w) BLG. It is even more preferred that the whey protein
solution comprises at least 4% (w/w) BLG.
Higher concentrations of BLG are even more preferred and preferably the whey protein solution
comprises at least 6% (w/w) BLG. More preferably the whey protein solution comprises at least
10% (w/w) BLG. It is even more preferred that the whey protein solution comprises at least
% (w/w) BLG.
In some preferred embodiments of the invention the whey protein solution of step a) comprises
in the range of 04—40% (w/w) BLG relative to the weight of the whey protein solution. Prefera—
bly the whey n solution comprises in the range of 1-35% (w/w) BLG. More preferably the
whey protein solution comprises in the range of 4—30% (w/w) BLG. It is even more preferred
that the whey protein solution comprises in the range of 10—25% (w/w) BLG.
Any suitable whey protein source may be used to prepare the whey protein solution. In some
preferred embodiments of the invention the whey protein solution comprises, or even ts
of, a milk serum protein concentrate, whey protein concentrate, milk serum protein isolate,
whey protein e, or a ation thereof.
It is red that the whey protein solution is a demineralised whey protein solution.
In this context the term demineralised means that the conductivity of the whey protein solution
is at most 15 mS/cm, and preferably at most 10 mS/cm, and even more preferably at most 8
mS/cm. The UF te conductivity of a ralised whey protein solution is preferably at
most 7 mS/cm, more preferably at most 4 mS/cm, and even more preferably at most 1 mS/cm.
It is particularly preferred that the whey protein solution is a demineralised milk serum protein
concentrate, a demineralised milk serum protein isolate, a demineralised whey protein concen—
trate, or a demineralised whey protein isolate.
W0 2018!115520 2017/084553
In some particularly preferred embodiments of the invention the whey protein solution compris—
es, or even consists of, a demineralised and pH adjusted milk serum n concentrate, whey
protein concentrate, milk serum protein isolate, whey protein isolate, or a combination thereof.
The whey protein solution may for example comprise, or even consist of, a demineralised milk
serum n concentrate. Alternatively, the whey protein solution may comprise, or even con—
sist of, a demineralised whey protein concentrate. Alternatively, the whey protein on may
comprise, or even consist of, a ralised milk serum protein isolate. Alternatively, the
whey protein solution may comprise, or even consist of, a demineralised whey n isolate.
In the context of the present invention, the terms “whey protein concentrate” and “milk serum
protein concentrate" pertains to preparations of whey or milk serum which preparations contain
in the range of approx. 20-89% (w/w) protein relative to total solids.
In the context of the present invention, the terms “whey protein isolate" and “milk serum pro—
tein isolated” pertains to preparations of whey or milk serum which preparations contain at
least 90% (w/w) n relative to total solids.
The terms “consists essentially of" and “consisting essentially of” mean that the claim or feature
in question encompasses the ied materials or steps and those that do not materially affect
the basic and novel teristic(s) of the claimed invention.
The protein of the whey protein solution is preferably derived from mammal milk, and prefera—
bly from the milk of a ruminant such as e.g. cow, sheep, goat, o, camel, llama, mare
and/or deer. Protein derived from bovine (cow) milk is particularly preferred. The BLG and the
additional whey protein are therefore preferably bovine BLG and bovine whey n.
The protein of the whey protein solution is preferably as close to its native state as possible and
3O preferably have only been subjected to gentle heat—treatments if any at all.
In some preferred embodiments of the invention the BLG of the whey protein solution has a
degree of ylation of at most 1. Preferably, the BLG of the whey protein solution has a de-
gree of lactosylation of at most 0.6. More ably, the BLG of the whey protein solution has a
degree of lactosylation of at most 0.4. Even more preferably, the BLG of the whey protein solu-
tion has a degree of lactosylation of at most 0.2. Most ably, the BLG of the whey protein
solution has a degree of lactosylation of at most 0.1, such as e.g. preferably at most 0.01.
W0 2018!115520 2017/084553
The degree of lactosylation of BLG is determined according to nka et al (J. Agric. Food
Chem., Vol. 54, No. 23, 2006, pages 8874—8882).
In some preferred ments of the invention the whey n solution has a furosine value
of at most 80 mg/100 g protein. Preferably, the whey protein on has a furosine value of at
most 40 mg/100 g protein. More preferably, the whey protein solution has a furosine value of
at most 20 mg/100 g protein. Even more preferably, the whey protein solution has a furosine
value of at most 10 mg/100 g protein. Most preferably, the whey n solution has a furosine
value of at most 5 mg/100 g protein, such as e.g. preferably a furosine value of 0 mg/100 g
protein.
The whey protein solution typically contains other components in addition to protein. The whey
protein solution may contain other components that are ly found in whey or milk serum,
such as e.g. minerals, carbohydrate, and/or lipid. Alternatively or additionally, the whey protein
on may contain components that are not native to the whey or milk serum. However, such
non-native components should preferably be safe for use in food production and preferably also
for human consumption.
The present method is particularly advantageous for separating BLG from crude whey protein
solutions that contain other solids than BLG.
The whey protein solution may for example contain carbohydrates, such as e.g. lactose, oligo—
saccharides and/or hydrolysis products of lactose (i.e. glucose and galactose). The whey protein
solution may e.g. n carbohydrate in the range of 0—40% (w/w), such as in the range of 1—
30% (w/w), or in the range of 2—20% (w/w).
In some preferred embodiments of the ion the whey protein solution contains at most
% (w/w) carbohydrate, preferably at most 10% (w/w) carbohydrate, more preferably at
most 5% (w/w) carbohydrate, and even more preferably at most 2% (w/w) carbohydrate.
The whey protein solution may also comprise lipid, e.g. in the form of triglyceride and/or other
lipid types such as phospholipids.
In some embodiments of the invention the whey protein solution of step a) comprises a total
amount of lipid of at most 15% (w/w) ve to total solids. ably, the whey protein solu-
tion of step a) comprises a total amount of lipid of at most 10% (w/w) relative to total solids.
More ably, the whey protein solution of step a) comprises a total amount of lipid of at
most 6% (w/w) relative to total solids. Even more preferably, the whey protein solution of step
a) comprises a total amount of lipid of at most 1.0% (w/w) relative to total solids. Most prefer—
W0 2018!115520
ably, the whey protein on of step a) comprises a total amount of lipid of at most 0.5%
(w/w) relative to total solids.
The total amount of protein of the whey protein solution is typically at least 1% (w/w) relative
to the weight of the whey protein solution. Preferably, the total amount of protein of the whey
protein solution is at least 5% (w/w). More preferred, the total amount of protein of the whey
protein solution is at least 10% (w/w). Even more preferred, the total amount of protein of the
whey protein solution is at least 15% (w/w).
In some preferred embodiments of the invention the total amount of protein of the whey pro—
tein solution is in the range of 1—50% (w/w). Preferably, the total amount of protein of the
whey protein solution is in the range of 5—40% (w/w). More preferred, the total amount of pro—
tein of the whey protein solution is in range of 10—30% (w/w). Even more red, the total
amount of protein of the whey protein solution is in the range of 15-25% (w/w).
The total amount of protein of the whey protein solution is determined according to Example
9.2.
The whey n on is typically prepared by subjecting a whey protein feed to one or
more adjustments which form the whey protein solution which is supersaturated with respect to
BLG.
The feed is preferably a WPC, a WPI, a SPC, a SPI, or a combination thereof.
In the context of the present ion, the term “whey protein feed” pertains to the composi—
tion that is transformed to the whey protein solution supersaturated with respect to BLG. The
whey protein feed is typically an aqueous liquid comprising BLG and at least one additional
whey protein, but is normally not supersaturated with respect to BLG.
3O The embodiments relating to the chemical composition of the whey protein solution y
apply to the whey protein feed, r typically at least one parameter of the whey protein
feed is set to avoid supersaturation or at least spontaneous cwstallisation.
In some red embodiments of the invention the supersaturated whey protein solution is
prepared by subjecting the whey n feed to one or more of the following adjustments:
— Adjusting the pH,
— Reducing the conductivity
- ng the temperature
— Increasing the protein concentration
40 - Adding an agent that s the water activity
W0 2018!115520
— Modifying the ion composition
In some preferred embodiments of the invention the preparation of the whey protein solution
involves adjusting the pH of the whey protein feed to a pH in the range of 5—6.
All pH values are measured using a pH glass electrode and are normalised to 25 s C.
The whey protein solution may for example have a pH in the range of 4.9—6.1. The pH of the
whey protein solution may e.g. be in the range of 5.0—6.1. Alternatively, the pH of the whey
protein solution may be in the range of 5.1—6.1. Preferably, the pH of the whey protein solution
is in the range of 0.
In some preferred embodiments of the invention the pH of the whey protein solution is in the
range of 5.0-6.0. Preferably, the pH of the whey protein solution is in the range of 5.1-6.0.
More preferably the pH of the whey protein solution is in the range of 5.1—5.9. Even more pre—
ferred, the pH of the whey protein solution may be in the range of 5.2-5.9. Most preferably the
pH of the whey protein solution is in the range of 5.2—5.8.
The pH is preferably adjusted using food acceptable acids and/or bases. Food acceptable acids
are particularly red, such as e.g. carboxylic acids. Useful examples of such acids are e.g.
hloric acid, sulfuric acid, phosphoric acid, acetic acid, maleic acid, ic acid, lactic
acid, citric acid, or gluconic acid, and/or mixtures thereof.
In some preferred embodiments of the invention the pH is adjusted using a e, such as
e.g. D-glucono—delta-Iactone, which slowly hydrolyses and at the same time reduces the pH of
the aqueous liquid containing it. The target pH after the hydrolysis of the lactone has ended can
be ated ely.
Useful examples of food acceptable bases are e.g. hydroxide sources such as e.g. sodium hy—
3O droxide, potassium hydroxide, calcium hydroxide, salts of food acids such as e.g. tri—sodium
citrate, and/or combinations thereof.
In other preferred embodiments of the invention the pH is ed by addition of cation ex-
change material on its H+ form. ype/large particle type cation exchange material is easily
removed from the whey protein solution prior to the crystallisation or even after the crystallisa-
tion. Adjustment of pH by addition of cation exchange material on its H+ form is particularly
advantageous in the present invention as it reduced the pH without adding negative counter
ions that icantly affects the conductivity of the whey protein feed.
W0 2018!115520
In some red embodiments of the invention the preparation of the whey protein solution
involves reducing the conductivity of the whey protein feed.
Conductivity values mentioned herein have been normalised to 25 degrees C unless it is speci—
fied otherwise.
The inventors have found that reducing the conductivity of the whey protein on leads to a
higher yield of BLG crystals. The minimum obtainable conductivity of the whey protein solution
depends on the composition of the protein fraction and the lipid fraction (if any). Some protein
species such as e.g. caseinomacropeptide (CMP) contribute more to the conductivity than other
protein species. It is therefore preferable that the conductivity of the whey protein feed is
t near the level where protein and the counter ions of the protein are the main contribu—
tors to the conductivity. The reduction of conductivity often involves l of at least some of
the small, free ions that are present in liquid phase and not tightly bound to the proteins.
It is often preferred that the whey protein solution has a conductivity of at most 10 mS/cm. In
some preferred embodiments of the ion, the whey protein solution has a conductivity of
at most 5 mS/cm. Preferably, the whey protein solution has a tivity of at most 4 mS/cm.
Lower conductivities are even more preferred and give rise to higher yields of BLG crystals.
Thus, the whey protein solution preferably has a conductivity of at most 3 mS/cm. In some
preferred embodiments of the invention, the whey protein solution has a conductivity of at most
1 mS/cm. Preferably, the whey protein on has a conductivity of at most 0.5 mS/cm.
The conductivity of the whey protein feed is preferably reduced by dialysis or diafiltration. Dia—
filtration by ultrafiltration is particularly preferred as it allows for washing out salts and small
charged molecules while ns are retained. In some preferred embodiments of the inven—
tion, the same UF unit is used for UF/diafiltration and subsequent concentration of the whey
protein feed.
The present inventors have seen indications that the ratio between the conductivity ssed
in mS/cm) and the total amount of protein in the whey protein solution ssed in % wt.
total protein relative to the total weight of the whey protein solution) ageously can be
kept at or below a certain threshold to facilitate the crystallisation of BLG.
In some preferred embodiments of the invention, the ratio between the conductivity and the
total amount of protein of the whey protein solution is at most 0.3. Preferably, the ratio be—
tween the conductivity and the total amount of protein of the whey n solution is at most
0.25. Preferably, the ratio n the conductivity and the total amount of protein of the whey
W0 15520 2017/084553
protein solution is at most 0.20. More preferably, the ratio between the conductivity and the
total amount of protein of the whey protein solution is at most 0.18. Even more ably, the
ratio between the conductivity and the total amount of protein of the whey protein solution is at
most 0.12. Most preferably, the ratio between the conductivity and the total amount of protein
of the whey protein solution is at most 0.10.
It is for example preferred that the ratio between the conductivity and the total amount of pro—
tein of the whey protein solution is approx. 0.07, or even lower.
The t inventors have furthermore found that the whey protein feed advantageously may
be conditioned to provide a whey protein solution having a UF permeate conductivity of at most
mS/cm. The UF permeate conductivity is a measure of the conductivity of the small molecule
fraction of a liquid and is measured ing to Example 9.10. When the term “conductivity“ is
used herein as such it refers to the conductivity of the liquid in question. When the term “UF
permeate conductivity” is used it refers to the conductivity of the small molecule fraction of a
liquid and is measured according to Example 9.10.
Preferably, the UF permeate conductivity of the whey protein solution is at most 7 mS/cm. More
ably, the UF permeate conductivity of the whey protein on may be at most 5
mS/cm. Even more preferably, the UF permeate tivity of the whey protein solution may
be at most 3 mS/cm.
Even lower UF permeate conductivities may be used and are particularly red if a high
yield of BLG should be obtained. Thus, preferably, the UF permeate conductivity of the whey
protein solution is at most 1.0 mS/cm. More ably, the UF permeate tivity of the
whey protein solution may be at most 0.4 mS/cm. Even more preferably, the UF permeate con—
ductivity of the whey protein solution may be at most 0.1 mS/cm. Most preferably, the UF per—
meate conductivity of the whey protein solution may be at most 0.04 mS/cm.
3O Even lower UF permeate conductivities may reached, e.g. of MilliQ water is used as a diluent in
during tration (MilliQ water has a tivity of approx. 0.06 uS/cm) Thus, the UF perme—
ate conductivity of the whey protein solution may be at most 0.01 mS/cm. Alternatively, the UF
permeate conductivity of the whey protein solution may be at most 0.001 mS/cm. Alternatively,
the UF permeate conductivity of the whey protein solution may be at most 0.0001 mS/cm.
In some preferred embodiments of the invention the preparation of the whey protein solution
involves reducing the temperature of the whey protein feed.
W0 2018!115520
For example, the preparation of the whey protein solution may involve reducing the tempera—
ture of the whey protein feed to at least 5 degrees C, preferably at least 10 degrees C and even
more preferred at least 15 degrees C. For example, the preparation of the whey protein on
may involve reducing the temperature of the whey protein feed to at least 20 degrees C.
The temperature of the whey protein feed may e.g. be reduced to at most 30 degrees C, pref—
erably at most 20 degrees C, and even more preferably to at most 10 degrees C. The inventors
have found that even lower temperatures provide higher degree of supersaturation, thus, the
temperature of the whey protein feed may e.g. be reduced to at most 5 degrees C, preferably
at most 2 degrees C, and even more ably to at most 0 degrees C. The temperature may
even be lower than 0 degrees C, however preferably the whey protein solution should remain
pumpable, e.g. in the form of an ice slurry.
In some preferred embodiments of the invention the whey protein solution is an ice slurry be-
fore the initialisation of BLG llisation. Alternatively or additionally, crystallising whey pro—
tein solution may be converted into or maintained as an ice slurry during the BLG crystallisation
of step b).
In some ularly preferred embodiments of the invention the preparation of the whey pro—
tein solution involves increasing the total protein tration of the whey protein feed. The
whey n feed may e.g. be subjected to one or more protein concentration steps such as
iltration, ltration, reverse osmosis, and/or evaporation and thereby concentrated to
obtain the whey protein solution.
Ultrafiltration is particularly preferred as it allows for selective concentration of n while the
concentrations of salts and carbohydrates are nearly unaffected. As mentioned above, ultrafil—
tration is preferably used both for diafiltration and concentration of the whey protein feed.
In some preferred embodiments of the invention, the concentration of BLG of whey protein so—
3O lution is below the level where spontaneous crystallisation of BLG occurs. It is therefore often
red to stop the cations of the whey protein feed when the whey protein solution is
in the meta—stable region, i.e. in the supersaturated region where BLG crystals can grow when
seeding is used but where crystallisation does not start spontaneously.
In some preferred embodiments of the invention the preparation of the whey protein solution
involves on of one or more water activity reducing agent(s) to the whey protein feed.
Useful, but miting, examples of such water activity reducing agents are ccharides
and/or poly-ethylene glycol (PEG).
W0 2018!115520
In some preferred embodiments of the invention the preparation of the whey protein solution
involves modifying the ion composition of the whey protein feed, e.g. by ion exchange, by add—
ing new ion species, by dialysis or diafiltration.
Typically, the whey n solution is prepared by combining two or more of the above process
steps for creating supersaturation.
In some preferred embodiments of the ion the preparation of the whey protein solution
involves subjecting the whey protein feed to at least:
— concentrating, e.g. using ultrafiltration, nanofiltration or reverse osmosis, at a temperature
above 10 degrees C, and
— uently cooling to a ature below 10 degrees C.
In other preferred embodiments of the ion the preparation of the whey protein solution
es subjecting the whey protein feed to at least
- concentrating at a pH above 6.0, and
— subsequently reducing the pH by addition of an acid (e.g. GDL or cation exchange material in
H+ form)
In yet other preferred embodiments of the invention the preparation of the whey protein solu—
tion es subjecting the whey protein feed to at least:
— reducing the conductivity, e.g. by diafiltration using a membrane that retains at least BLG.
In further preferred embodiments of the invention, the preparation of the whey protein solution
es subjecting the whey protein feed to a combination at least:
— ing the pH to 5—6,
— reducing the conductivity by diafiltration using a membrane that retains at least BLG,
— concentrating n, e.g. using ultrafiltration, nanofiltration or reverse osmosis, at a tem—
re above 10 degrees C, and
- finally, cooling to a temperature below 10 degrees C.
The present inventors have furthermore found that the BLG yield of the present method may be
improved by controlling the molar ratio between the sum of sodium+potassium vs. the sum of
calcium and magnesium. A higher relative amount of calcium and magnesium surprisingly
seems to increase the yield of BLG and therefore increases the efficiency of the BLG recovery of
the present method.
W0 2018!115520
In some preferred embodiments of the present invention the whey protein solution of step a)
has a molar ratio between Na + K and Ca + Mg of at most 4. More preferably, the whey protein
solution of step a) has a molar ratio between Na + K and Ca + Mg of at most 2. Even more
preferably, the whey n on of step a) has a molar ratio between Na + K and Ca + Mg
of at most 1.5, and even more preferably at most 1.0. Most preferably, the whey protein solu—
tion of step a) has a molar ratio between Na + K and Ca + Mg of at most 0.5, such as e.g. at
most 0.2.
The molar ratio between Na + K and Ca + Mg it calculated as (mNa+mK)/(mCa+mMg) wherein
mNa is the content of elemental Na in mol, mK is the content of elemental K in mol, mCa is the
content of elemental Ca in mol, and mm is the content of elemental Mg in mol.
It is particularly preferred that the whey protein solution has been supersaturated with respect
to BLG by salting-in and that BLG therefore can be crystallised from the whey protein solution
in salting—in mode.
In some ments of the invention the whey protein solution has low content of denatured
protein, particularly if the edible BLG product of the present invention should have degree of
protein denaturation too. Preferably, the whey protein solution has a degree of protein denatur—
ation of at most 2%, preferably at most 1.5%, more preferably at most 1.0%, and most prefer—
ably at most 0.8%.
Step b) of the method involves crystallising at least some of the BLG of the supersaturated
whey n solution.
It is particularly preferred that the crystallisation of step b) takes place in salting—in mode, i.e.
in a liquid that has a low ionic strength and tivity. This is contrary to the salting—out
mode wherein significant amounts of salts are added to a solution in order to provoke crystalli—
sation.
The crystallisation of BLG of step b) may e.g. involve one or more of the ing:
— Waiting for crystallisation to take place,
- Addition of llisation seeds,
- Increasing the s of supersaturation of BLG even further, and/or
— Mechanical stimulation.
In some preferred embodiments of the invention step b) involves adding crystallisation seeds to
the whey protein solution. The inventors have found that on of crystallisation seeds makes
it possible to l when and where the BLG crystallisation takes place to avoid sudden clog—
W0 2018!115520
ging of process equipment and unintentional stops during production. It is for example often
ble to avoid onset crystallisation while concentrating the whey n feed.
In principle any seed material which initiates the crystallisation of BLG may be used. However,
it is red that hydrated BLG crystals or dried BLG crystals are used for seeding to avoid
adding additional impurities to the whey protein solution.
The crystallisation seeds may be on dry form or may form part of a suspension when added to
the whey protein solution. Adding a suspension containing the crystallisation seeds, e.g. BLG
crystals, is presently preferred as it appears to provide a faster onset of llisation. It is
preferred that such a sion contain crystallisation seeds has a pH in the range of 5—6 and
a conductivity of at most 10 mS/cm.
In some embodiments of the invention at least some of the crystallisation seeds are located on
a solid phase which is brought in contact with the whey protein solution.
The crystallisation seeds ably have a smaller particle size than the desired size of the BLG
crystals. The size of the cwstallisation seeds may be modified by removing the largest seeds by
sieving or other size fractionation processes. Particle size reduction, e.g. by means of grinding,
may also be employed prior to the particle size fractionation.
In some ments of the invention at least 90% (w/w) of the crystallisation seeds have a
particle size (measured by sieving analysis) in the range of 0.1—600 s. For example, at
least 90% (w/w) of the crystallisation seeds may have a particle size in the range of 1—400 mi—
crons. Preferably, at least 90% (w/w) of the crystallisation seeds may have a particle size in the
range of 5—200 microns. More preferably, at least 90% (w/w) of the crystallisation seeds may
have a particle size in the range of 5-100 microns.
The particle size and dosage of crystallisation seeds may be tailored to provide the optimal
3O crystallisation of BLG.
In some preferred embodiments of the invention the crystallisation seeds are added to the
whey protein feed prior to obtaining aturation with respect to BLG but ably in a way
that at least some crystallisation seeds are still present when supersaturation is reached. This
may e.g. be accomplished by adding llisation seeds when the whey protein feed is close
to supersaturation, e.g. during cooling, concentration, and/or pH adjustment and to reach su—
persaturation before the crystallisation seeds are completely dissolved.
W0 2018!115520
In some preferred embodiments of the invention step b) involves increasing the degree of su—
persaturation of BLG even further, preferably to a degree where crystallisation of BLG initiates
ately, i.e. in at most 20 minutes, and preferably in at most 5 s. This is also re—
ferred to as the nucleation zone wherein crystallites form spontaneously and start the crystalli—
sation process.
The degree of supersaturation may e.g. be increased by one or more of the following:
- increasing the protein concentration of the whey protein solution further
— cooling the whey protein solution r
— bringing the whey protein solution closer to the optimum pH for BLG crystallisation
— reducing the conductivity even further.
In some preferred embodiments of the invention step b) involves g for the BLG crystals to
form. This may take several hours and is typically for a whey protein solution which is only
slightly supersaturated with respect to BLG and to which no crystallisation seeds have been
added.
In some preferred embodiments of the invention the provision of the whey protein solution
(step a) and the crystallisation of BLG (step b) takes place as two separate steps.
However, in other preferred embodiments of the invention step b) involves additional adjust—
ment of the crystallising whey protein on to raise the degree of supersaturation of BLG, or
at least in supersaturation. The additional adjustment results in an increased yield of
BLG crystals.
Such additional adjustment may involve one or more of:
- increasing the protein concentration of the crystallising whey protein solution even fur—
ther
- cooling the llising whey protein solution to an even lower temperature
- bringing the crystallising whey protein solution even closer to the m pH for BLG
crystallisation
- reducing the conductivity of the crystallising whey protein solution even further.
In some preferred embodiments of the invention the crystallising whey protein solution is main—
tained in the meta—stable zone during step b) to avoid spontaneous ion of new crystal—
lites.
The inventors have ined the l lattice structure of the isolated BLG crystals by x-ray
crystallography and have not found a similar crystal in the prior art.
In some preferred embodiments of the invention at least some of the BLG crystals obtained
during step b) have an orthorhombic space group P 21 21 21.
ably, at least some of the obtained BLG crystals have an orthorhombic space group P 21
21 21 and the unit cell dimensions a=68.68 (5%) A, b = 68.68 (15%) A, and c = 156.65
(i5%) A; and unit cell integral angles o=90°, B=90°, and y=90°.
In some preferred embodiments of the invention, at least some of the obtained BLG crystals
have an orthorhombic space group P 21 21 21 and the unit cell dimensions a=68.68 (:|:2%) lgi, b
= 68.68 (:l:2%) A, and c = 156.65 (:l:2%) A; and the unit cell integral angles o=90°, B=90°,
and y=90°.
Even more preferred, at least some of the obtained BLG ls may have an orthorhombic
space group P 21 21 21 and the unit cell dimensions a=68.68 (:L'l%) lgi, b = 68.68 (:|:1°/o) A, and
c = 156.65 (:|:1%) A; and the unit cell integral angles o=90°, B=90°, and y=90°.
Most preferably, at least some of the obtained BLG ls have an orthorhombic space group
P 21 21 21 and the unit cell dimensions a=68.68 A, b = 68.68 A, and c = 156.65 A; and the unit
cell integral angles o=90°, B=90°, and y=90°.
In some particularly preferred embodiments of the invention the method ns a step c) of
separating at least some of the BLG crystals from the remaining whey protein solution. This is
especially preferred when purification of BLG is desired.
Step c) may for example comprise separating the BLG crystals to a solids content of at least
% (w/w). Preferably, step c) comprises separating the BLG crystals to a solids content of at
least 40% (w/w). Even more preferably step c) comprises separating the BLG crystals to a sol—
ids content of at least 50% (w/w).
The inventors have found that the high solids content is ageous for the purification of
BLG as the aqueous n that adhere to the separated BLG crystals lly contains the
impurities that should be avoided. Additionally, the high solids content reduces the energy con—
on for converting the separated BLG crystals to a dry product, such as e.g. a powder,
and it ses the BLG yield obtained from a drying unit with a given capacity.
In some preferred embodiments of the invention step c) comprises separating the BLG crystals
to a solids content of at least 60%. Preferably, step c) comprises separating the BLG crystals to
a solids t of at least 70%. Even more preferably step c) comprises ting the BLG
crystals to a solids content of at least 80%.
RECTIFIED SHEET (RULE 91) ISA/EP
W0 2018!115520
In some preferred embodiments of the invention the tion of step c) involves one or more
of the following operations:
- centrifugation,
— decantation,
- filtration,
— sedimentation,
- ations of the above.
These unit operations are well—known to the person skilled in the art and are easily implement-
ed. Separation by filtration may e.g. involve the use of vacuum filtration, dynamic cross—flow
filtration (DCF), a filtrate press or a filter centrifuge.
Different pore sizes for filtration may be employed based on the d e. Preferably,
the filter allows native whey protein and small aggregates to pass but retains the BLG crystals.
The filter preferably has a nominal pore size of at least 0.1 micron. The filter may e.g. have a
nominal pore size of at least 0.5 micron. Even more preferably, the filter may have a nominal
pore size of at least 2 micron.
s having larger pore sizes can also be used and are in fact preferred if primarily the large
crystals should be separated from a liquid containing BLG crystals. In some embodiments of the
invention the filter has a nominal pore size of at least 5 micron. ably, the filter has a nom—
inal pore size of at least 20 micron. Even more preferably, the filter may have a pore size of at
least 40 micron.
The filter may e.g. have a pore size in the range of 0.03—5000 micron, such as e.g. 0.1—5000
micron. Preferably, the filter may have a pore size in the range of 0.5-1000 micron. Even more
preferably, the filter may have a pore size in the range of 5—800 micron, such as e.g. in the
range of 10-500 micron or in the range of 50—500 microns.
In some red embodiments of the invention the filter has a pore size in the range of 0.03—
100 micron. Preferably, the filter may have a pore size in the range of 0.1-50 micron. More
preferably, the filter may have a pore size in the range of 4—40 micron. Even more preferably,
the filter may have a pore size in the range of 5—30 micron such as in the range of 10—20 mi—
CI’OI’L
An advantage of using s having a pore size larger than 1 micron is that bacteria and other
microorganisms also are at least partly removed during separation and optionally also during
washing and/or recrystallization. The present method therefore makes it possible to produce
40 high purity BLG with both a very low bacterial load yet avoiding heat—damage of the protein.
W0 2018!115520
Another advantage of using filters having a pore size larger than 1 micron is that removal of
water and subsequent drying becomes easier and less energy ing.
The remaining whey protein solution which is separated from the BLG crystals may be recycled
to the whey protein feed during preparation of the whey protein solution.
In some red embodiments of the invention, step c) employs a filter centrifuge. In other
preferred ments of the invention, step c) employs a decanter centrifuge. Initial results
(see e 13) have shown that use a filter centrifuge and/or a decanter centrifuge for sepa—
rating BLG crystals from the mother liquor provides more robust operation of the method than
e.g. vacuum filtration.
Often it is preferred to dry a formed filter cake with a drying gas to reduce the moisture content
of the filter cake and preferably to make it possible to peel the filter cake off the filter. The use
of a drying gas may form part of the separation step or alternatively, the final drying step if the
filter cake is converted directly to a dry edible BLG composition.
In some preferred embodiments of the invention, step c) s a DCF unit.
Initial tests (see example 12) have shown that using a DCF unit with a membrane pore size in
the range of 0.03—5 , and ably in the range of 0.3—1.0 microns, offers an efficient
separation of BLG crystals and the inventors have observed that the DCF unit can be run for a
duration sufficient to separate crystals from even large batches of whey protein solution con—
taining BLG crystals.
In some preferred embodiments of the invention step c) is performed using a DCF unit
ed with a membrane capable of retaining BLG crystals, the DCF permeate is recycle to
form part of the whey protein solution or whey protein feed, and DCF retentate may be recov—
3O ered or returned to the crystallization tank. ably, the DCF permeate is treated, e.g. by
ultra-/diafiltration by to make it supersaturated with respect to BLG prior to mixing with the
whey protein solution or whey protein feed.
Advantageously, these embodiments do not require that the temperature of the liquid streams
are raised above 15 s C and are therefore less prone to microbial contamination than
method variants that e higher temperatures. Another industrial advantage of the these
embodiments is that the level of supersaturation is easily controlled and can be kept at a level
where unwanted, spontaneous crystallization does not occur. The temperature of the liquid
streams during these ments of the method is therefore preferably at most 15 degrees C,
W0 2018!115520
more preferred at most 12 s C, and even more preferred at most 10 degrees C, and
most preferred at most 5 degrees C.
These embodiments are exemplified in Example 10 and illustrated in figure 26. These embodi—
ments may be implemented as a batch methods or a continuous method.
In some preferred embodiments of the invention the method comprises a step d) of washing
BLG crystals, e.g. the separated BLG crystals of c). The washing may consist of a single wash or
of multiple washing steps.
The washing of step d) preferably involves contacting the BLG crystals with a washing liquid
without completely dissolving the BLG crystals and subsequently separating the remaining BLG
crystals from the washing liquid.
The washing liquid is preferably selected to avoid te ution of the BLG crystals and
may e.g. comprise, or even consist essentially of, cold demineralised water, cold tap water, or
cold reverse osmosis permeate.
The washing liquid may have a pH in the range of 5—6, preferably in the range of 5.0—6.0, and
even more preferably in the range of 0, such as e.g. in the range of 5.1—5.9.
The washing liquid may have a conductivity of at most 0.1 mS/cm, preferably at most 0.02
mS/cm, and even more preferably at most 0.005 mS/cm.
Washing s having even lower conductivities may be used. For example, the washing liquid
may have a conductivity of at most 1 microS/cm. Alternatively, the washing liquid may have a
conductivity of at most 0.1 microS/cm, such as e.g. approx. 0.05 microS/cm.
A washing step is preferably med at low temperature to limit the dissolution of l—
3O lised BLG. The ature of the washing liquid is preferably at most 30 degrees C, more
preferably at most 20 degrees C and even more ably at most 10 degrees C.
A g step may e.g. be performed at at most 5 degrees C, more preferably at at most 2
degrees C such as e.g. approx. 0 degrees C. Temperatures lower than 0 degrees C may be used
in so far that the washing liquid does not freeze at that temperature, e.g. due to the presence
of one or more freezing point depressant(s).
W0 2018!115520
In some embodiments of the ion the washing liquid contains BLG, e.g. in an amount of at
least 1% (w/w), and preferably in an amount of at least 3% (w/w), such as e.g. in an amount
of 4% (w/w).
The washing of step d) typically dissolves at most 80% (w/w) of the initial amount of BLG crys—
tals, preferably at most 50% (w/w), and even more preferably at most 20% (w/w) of the initial
amount of BLG crystals. Preferably, the washing of step d) dissolves at most 15% (w/w) of the
initial amount of BLG crystals, more preferably at most 10% (w/w), and even more preferably
at most 5% (w/w) of the initial amount of BLG crystals.
The weight ratio between the total amount of washing liquid and the initial amount of separated
BLG crystals is often at least 1, preferably at least 2 and more ably at least 5. For exam—
ple, the weight ratio between the amount of washing liquid and the initial amount of separated
BLG crystals may be at least 10. atively, the weight ratio between the amount total of
washing liquid and the initial amount of separated BLG crystals may be at least 20, such as e.g.
at least 50 or at least 100.
The term “total amount of washing liquid” pertains to the total amount of washing liquid used
during the entire process.
In some preferred embodiments of the invention the one or more g sequences take place
in the same filter arrangement or in a r filter arrangement as the BLG crystal separation.
A filter cake primarily containing BLG crystals is added one or more sequences of washing liquid
which is removed h the filter while the remaining part of the BLG crystals stays in the
filter cake.
In particularly preferred ments of the invention, the separation of step c) is performed
using a filter that retains BLG crystals. Subsequently, the filter cake is contacted with one or
more quantities of washing liquid which moves through the filter cake and the . It is often
3O preferred that each quantity of washing liquid is at most 10 times the volume of the filter cake,
preferably at most 5 times the volume of the filter cake, more preferably at most 1 times the
volume of the filter cake, even more preferably at most 0.5 times the volume of the filter cake,
such as e.g. at most 0.2 times the volume of the filter cake. The volume of the filter cake in-
cludes both solids and fluids (liquids and gasses) of the filter cake. The filter cake is preferably
washed this way at least 2 times, preferably at least 4 times and even more preferably at least
6 times.
The used g liquid from step d) may e.g. be recycled to the whey protein feed or the
whey protein solution where washed out BLG may be isolated again.
W0 2018!115520
The method may rmore comprise a step e) which involves a recrystallization step com—
prising:
— dissolving the separated BLG ls in a recrystallization liquid,
— adjusting the recrystallization liquid to obtain supersaturation with respect to BLG,
— crystallising BLG in the supersaturated, ed recrystallization liquid, and
— separating BLG crystals from the remaining ed recrystallization liquid.
Step e) may comprise either a single re—crystallisation sequence or multiple re—crystallisation
ces.
In some embodiments of the invention the BLG crystals of step or c) or d) are recrystallized at
least 2 times. For example, the BLG crystals may be recrystallized at least 3 times, such as e.g.
at least 4 times.
The washing and re-crystallization steps may be combined in any sequence and may be per—
formed multiple times if required.
The separated BLG crystals of step c) may e.g. be subjected to the process sequence:
- One or more steps of g (step d), followed by
- One or more steps of re—crystallisation (step e).
Alternatively, the separated BLG crystals of step c) may be subjected to the process sequence:
— One or more steps of re—crystallisation (step e), followed by
- One or more steps of washing (step d).
It is also possible to combine multiple steps of washing and re—crystallisation, e.g. in the se—
- One or more steps of washing (step d),
— One or more steps of re—crystallisation (step e),
- One or more steps of washing (step d), and
3O — One or more steps of re—crystallisation (step e).
Or e.g. in the sequence:
— One or more steps of re—crystallisation (step e),
— One or more steps of washing (step d),
— One or more steps of re—crystallisation (step e).
- One or more steps of washing (step d)
In some ments of the invention the method furthermore involves subjecting the sepa—
rated BLG to additional BLG enrichments steps, e.g. based on tography or selective fil—
40 tration. However, in other preferred embodiments of the invention the method does not contain
W0 2018!115520
additional BLG enrichment steps after step b). By the term “additional BLG enrichment step” is
meant a process step which enriches BLG relative to the total amount of protein, which step is
not related to crystallisation of BLG or handling of BLG crystals. An example of such an addi—
tional BLG enrichment step is ion exchange chromatography. Washing of BLG crystals and/or
recrystallization of BLG is not considered “additional BLG enrichment .
In some particularly preferred embodiments of the invention the method involves a drying step
f) wherein a BLG—containing composition derived from steps b), c), d), or e) is converted to a
dry composition.
In the context of the present invention, the term “dry” means that the composition or product
in question comprises at most 6% (w/w) water and preferably even less.
In the context of the present invention, the term “BLG-containing ition” is used to de-
scribe the composition that is subjected to the drying of step f).
In the t of the present invention, a ontaining composition derived from step b), c),
d), or e)" means a composition which comprises at least some of the BLG from step b), c), d),
or e). In some preferred ments of the invention the “BLG—containing composition derived
from step b), c), d), or e)" is ly obtained from step b), c), d), or e). However, in other
preferred embodiments of the invention the “BLG—containing composition derived from step b),
c), d), or e)” is the result of further processing of the composition obtained directly from step
b), c), d), or e).
It is often red that the BLG—containing ition contains a significant amount of the
BLG present in the composition obtained directly from step b), c), d), or e). In some red
embodiments of the invention the BLG—containing composition derived from step b), c), d), or
e) comprises at least 50%(w/w) of the BLG obtained from step b), c), d), or e), ably at
least 70%, and even more preferably at least 80%.
Preferably, the BLG—containing composition derived from step b), c), d), or e) comprises at
least 85%(w/w) of the BLG obtained from step b), c), d), or e). More preferably, the BLG-
containing composition derived from step b), c), d), or e) comprises at least 90%(w/w) of the
BLG obtained from step b), c), d), or e). Even more preferably, the BLG—containing composition
derived from step b), c), d), or e) comprises at least 95%(w/w) of the BLG obtained from step
b), c), d), or e). Most ably, the BLG—containing ition derived from step b), c), d),
or e) comprises 100%(w/w) of the BLG obtained from step b), c), d), or e).
W0 2018!115520
In some preferred ments of the invention the drying step involves one or more of spray
, freeze drying, spin—flash drying, rotary drying, and/or fluid bed drying.
In some ularly preferred embodiments of the invention the drying step involves a BLG—
containing composition in which the BLG crystal has been dissolved and wherein the resulting
powder does not contain BLG crystals formed by step b) or by re—crystallisation prior to the
drying step. These embodiments are preferred if the edible BLG ition should resemble
that of e.g. a conventional, dried whey protein powder.
The BLG crystals may e.g. be dissolved by:
- increasing ature,
- increasing the conductivity, e.g. by addition of one or more salts
- changing the pH, e.g. outside the range 5—6,
- decreasing the concentration of BLG, e.g. by dilution,
— or a combination of the above.
Spray—drying is the presently preferred method of drying the BLG—containing composition which
does not n BLG crystals.
In other particularly preferred embodiments of the ion the drying step involves a BLG—
containing composition which still ns BLG crystals and wherein the resulting powder con—
tains BLG ls. These embodiments are preferred if the edible BLG composition should have
a higher density than tional, dried whey protein powder.
In some particularly preferred embodiments of the invention the drying step involves a BLG—
containing composition which still contains BLG crystals and n the resulting powder con—
tains BLG crystals. These embodiments are preferred if the edible BLG—composition should have
a higher density than conventional, dried whey protein powder.
3O As documented in Example 7, the present inventors have discovered that it is possible to spray—
dry a slurry of BLG crystals and retain at least some of the crystal structure when the dried BLG
crystals are resuspended in cold demineralised water. It is particularly advantageous to avoid
exposing the BLG-containing composition containing BLG crystals to a heat-treatment regime
that dissolve a significant amount of the BLG crystal prior to spraying. Thus, if pre—heating of
the BLG—containing composition containing BLG crystals is used prior to spraying it is preferred
to carefully control the heat-load.
In some ments of the invention the BLG—containing composition containing BLG crystals
has a temperature of at most 70 degrees C when reaching the exit of the spray device (e.g. a
W0 15520
nozzle or an atomizer), preferably at most 60 degrees C, more preferably at most 50 degrees
C. In some preferred embodiments of the invention the BLG—containing composition containing
BLG crystals has a temperature of at most 40 degrees C when reaching the exit of the spray—
device, preferably at most 30 degrees C, more preferably at most 20 s C, even more
preferably at most 10 degrees C, and most preferably at most 5 degrees C.
The spray—device of the spray—dryer is the device, e.g. the nozzle or the atomizer, which con—
verts the solution or suspension to be dried into droplets that enter the drying chamber of the
drier.
It is particularly preferred that the BLG—containing ition containing BLG crystals has a
temperature in the range of 0-50 degrees C when reaching the exit of the spray—device, prefer—
ably in the range of 2—40 degrees C, more preferably in the range of 4—35 degrees C, and most
preferably in the range of 5-10 degrees C when reaching the exit of the spray-device.
In some preferred embodiments of the ion, the BLG-containing composition has a crystal-
linity of BLG of at least 20% when reaching the exit of the spray—device, preferably at least
40%, more preferably at least 60%, even more preferably at least 80%, and a most preferably
at least 90%, such as e.g. preferably 97—100%. BLG—containing ition may either be a
BLG isolate, e.g. contain BLG in an amount of more than 90% (w/w) relative to total protein or
it may contain significant amounts of other proteins and therefore contain BLG in an amount of
at most 90% (w/w) relative to total protein.
In some preferred embodiments of the invention, the BLG-containing composition may have the
protein ition of a traditional liquid WPC or WPI or a traditional liquid SPC or SPI as de—
scribed herein but have a crystallinity of BLG of at least 20% when reaching the exit of the
spray-device, preferably at least 40%, more ably at least 60%, even more preferably at
least 80%, and a most preferably at least 90%, such as e.g. preferably 97—100%.
3O The inlet temperature of gas of the spray-drier is preferably in the range of 140—220 degrees C,
more preferably in the range of 160-200 degrees C, and even more preferably in the range of
0 degrees C, such as e.g. preferably approximately 180 degrees C. The exit temperature
of the gas from the spray-drier is ably in the range of 50-95 degrees C, more preferably
in the range of 70—90 degrees C, and even more preferably in the range of 80—88 s C,
such as e.g. preferably approximately 85 degrees C. As a rule of thumb, the solids that are sub—
jected to spray—drying are said to be heated to a temperature which is 10—15 degrees C less
than the gas exit temperature.
W0 2018!115520
In some preferred ments of the invention, the spray—drier is preferably in the range of
50—85 degrees C, more preferably in the range of 60—80 degrees C, and even more preferably
in the range of 65—75 degrees C, such as e.g. preferably approximately 70 degrees C.
The concept of spray—drying a suspension of BLG crystals has not been disclosed in the prior art
and is in itself separate aspect of the invention.
Therefore, an aspect of the invention pertains to a method of producing a spray—dried edible
powder composition comprising BLG, said composition comprising dried BLG ls, the meth—
od comprising the steps of:
— providing a liquid BLG—containing composition comprising BLG crystals, and preferably
having a llinity of BLG of at least 20%, said liquid BLG-containing composition
preferably comprising at least 10% (w/w) total solids, and preferably comprising at
least 5% (w/w) BLG, and
— atomizing the liquid ntaining composition into the drying r of an operat—
ing spray—dryer to convert the liquid BLG—containing composition comprising BLG crys—
tals to a powder.
In some preferred embodiments of the invention the BLG—containing composition to be dried is
mixed with a dry BLG isolate to raise the solids content to a level where the mixture can be
dried by fluid bed drying. This is also referred to as back—mixing and allows for very cost effi—
cient drying of the BLG product. These embodiments are ularly red for BLG-
containing compositions that contain BLG crystals.
An advantage of the present method is that the BLG—containing composition to be dried may
have a very high solids content prior to the drying step and therefore less water has to be re—
moved and less energy is ed in the drying operation.
In some preferred embodiments of the invention the BLG-containing composition d from
step b), c), d), or e) has a solids content of at least 20% (w/w). Preferably, the BLG—containing
composition derived from step b), c), d), or e) has a solids content of at least 30% (w/w). More
preferably, the BLG—containing composition derived from step b), c), d), or e) has a solids con—
tent of at least 40% (w/w). Even more preferably, the BLG—containing ition derived from
step b), c), d), or e) has a solids content of at least 50% (w/w), such as e.g. at least 60%
(w/w).
In other preferred embodiments of the invention the ntaining composition derived from
step b), c), d), or e) has a solids content of in the range of 20-80% (w/w). Preferably, the BLG-
containing composition derived from step b), c), d), or e) has a solids content in the range of
40 30-70% (w/w). More preferably, the BLG-containing composition derived from step b), c), d),
W0 2018!115520 2017/084553
or e) has a solids content in the range of 40—65% (w/w). Even more preferably, the BLG-
containing composition derived from step b), c), d), or e) has a solids t in the range of
50—65% (w/w), such as e.g. approx. 60% (w/w).
The present inventors have found that the higher the crystallinity of the BLG—containing compo—
sition, the less water is bound to the BLG—containing composition, and the higher total solids
content of the ntaining composition can be achieved prior to the drying step.
Thus in some preferred embodiments of the invention, the BLG—containing composition, has a
crystallinity of BLG of at least 10% (w/w). Preferably, the BLG of the BLG-containing composi—
tion has a llinity of at least 20% (w/w). More preferably the BLG of the BLG—containing
composition has a crystallinity of at least 30% (w/w). Even more preferably the BLG of the
BLG—containing composition has a crystallinity of at least 40% (w/w).
Even higher crystallinities are often preferred. Thus, in some preferred embodiments of the
invention the BLG of the BLG—containing composition has a crystallinity of at least 50% (w/w).
Preferably, the BLG of the BLG—containing composition has a crystallinity of at least 60% (w/w).
More preferably, the BLG of edible BLG composition has a crystallinity of at least 70% (w/w).
Even more preferably, the BLG of the BLG-containing composition has a crystallinity of at least
80% (w/w). Most preferred, the BLG of the BLG—containing composition has a crystallinity of at
least 90% (w/w), preferably at least 95% (w/w), more preferably at least 97% (w/w), and
even more preferably at least 99% (w/w).
The inventors have found that a reduced content of water tends to increase the crystallinity of
BLG of a composition. Thus, compositions having a high water:BLG ratio (e.g. a sion of
4% BLG crystals in water) tend to have a lower crystallinity of BLG than does itions
that have a lower water: BLG ratio (e.g. a filter cake or moist, isolated crystals) at the same
ions.
The method of the present invention may be operated using mild temperatures that do not
3O damage the nutritional value of neither BLG nor the other whey proteins of the whey protein
solution.
In some preferred embodiments of the invention, the BLG is not subjected to a temperature
above 90 degrees C during the method. Preferably, the BLG is not ted to a temperature
above 80 degrees C during the method. Even more preferred, the BLG is not subjected to a
temperature above 75 degrees C during the . It should be noted that even though
spray—drying often employs atures in the excess of 150 degree C, the short re
time and the concurrent evaporation of water means that the spray—dried proteins do not expe—
rience temperatures above 50—70 degrees C.
W0 2018!115520
The inventors have seen indications that extended heating during the drying step reduces the
amount of BLG that is in crystal form. In some preferred embodiments of the invention the heat
exposure during the drying step is kept sufficiently low to provide a degree of denaturation of
BLG of at most 10%, preferably at most 4%, more preferably at most 1%, even more prefera—
bly at most 0.4% and even more preferred at most 0.1%. Most preferably, the drying step does
not result in detectable denaturation of BLG at all.
The degree of denaturation caused by the drying step is calculated by determining the BLG con—
tent (relative to total solids) in the BLG—composition to be dried (cheforestepf) in step f) and the
BLG t (relative to total solids) in the redissolved, dried composition and using the formu—
Degree Of denatu ration = ((Cbefore step f ' Cafter step f)/Cbefore step f) * 1000/0
Some preferred embodiments of the ion pertain to a method of preparing an edible com—
on comprising beta-Iactoglobulin (BLG) in crystallised form, the method comprising the
steps of
a) providing a whey protein solution comprising BLG and at least one additional whey protein,
said whey protein solution is supersaturated with respect to BLG and has a pH in the range of
—6, said whey protein solution comprising:
— 70—100% (w/w) protein relative to total solids,
— 30—90% (w/w) BLG relative to total protein, and preferably 30—70% (w/w) BLG
— 4—50% (w/w) ALA relative to total n, and preferably 8—35% (w/w) ALA,
— 0-25% (w/w) CMP relative to protein,
— at least 10% (w/w) protein ve to the total weight of the whey protein solution,
b) crystallising BLG in the supersaturated whey protein solution, preferably by addition of crys—
tallisation seeds, and
f) drying the ntaining composition which is obtained directly from step b), said BLG-
containing composition preferably having a llinity of BLG of at least 30%,
which method does not contain steps c), d) or e).
The whey protein solution is preferably a ralised whey protein solution, and has prefera—
bly ratio n the conductivity and the total amount of protein of at most 0.3 and/or a UF
permeate conductivity of at most 7 mS/cm.
W0 2018!115520 2017/084553
In these embodiments the BLG crystals are not separated from the whey n solution but
are dried and results in a high density edible BLG composition in powder form.
The invention furthermore pertains to edible compositions obtainable by these ments.
Other preferred embodiments of the invention pertain to a method of preparing an edible com—
position comprising beta—lactoglobulin (BLG) in crystallised form, the method comprising the
steps of
a) providing a whey protein solution comprising BLG and at least one onal whey protein,
said whey protein solution is supersaturated with respect to BLG and has a pH in the range of
—6, said whey protein solution comprising:
— 70—100% (w/w) protein relative to total solids,
- 30-90% (w/w) BLG ve to total protein, and preferably 30-70%
- 4—50% (w/w) ALA relative to total protein, and preferably 8—35%
- 0—25% (w/w) CMP relative to total protein.
— at least 10% (w/w) protein relative to the total weight of the whey protein solution,
b) crystallising BLG in the supersaturated whey protein solution, preferably by addition of crys—
tallisation seeds,
c) ting BLG crystals from the remaining whey protein solution,
d) optionally, washing the separated BLG crystals obtained from step c),
e) optionally, re—crystallising BLG crystals ed from step c) or d), and
f) drying a BLG—containing composition derived from, and preferably directly obtained from,
step c), d), or e), which BLG-containing composition comprises BLG crystals and preferably
3O having a crystallinity of BLG of at least 30%.
The whey protein solution is preferably a demineralised whey protein solution, and has prefera—
bly ratio between the conductivity and the total amount of protein of at most 0.3 and/or a UF
permeate tivity of at most 7 mS/cm.
These embodiments are particularly useful for making low mineral and low phosphorus edible
BLG compositions in the form of high density powders
The invention furthermore pertains to an edible compositions obtainable by these embodiments.
W0 2018!115520
Yet other preferred embodiments of the invention pertain to a method of preparing an edible
composition sing beta—lactoglobulin in isolated form, the method comprising the steps of
a) providing a whey protein solution comprising BLG and at least one additional whey protein,
said whey protein solution is supersaturated with t to BLG and has a pH in the range of
—6, said whey protein solution comprising:
— % (w/w) protein relative to total solids,
— 30—90% (w/w) BLG relative to total protein, and preferably 30-70% (w/w) BLG,
— 5-50% (w/w) ALA relative to total protein, and preferably 8—35% (w/w) ALA,
— 0—25% (w/w) CMP relative to total protein.
— at least 10% (w/w) protein relative to the total weight of the whey protein solution,
b) crystallising BLG in the supersaturated whey protein on, preferably by addition of crys-
tallisation seeds,
c) separating BLG crystals from the remaining whey protein solution,
d) optionally, washing the ted BLG crystals obtained from step c),
e) optionally, re—crystallising BLG crystals obtained from step c) or d), and
f) drying a BLG—containing composition derived from step c), d), or e), which BLG—containing
ition does not comprise BLG ls.
The whey protein solution is ably a demineralised whey protein solution, and has prefera—
bly ratio between the conductivity and the total amount of protein of at most 0.3 and/or a UF
permeate conductivity of at most 7 mS/cm.
3O In these embodiments BLG crystals are dissolved prior to drying.
The invention furthermore pertains to an edible compositions obtainable by these embodiments.
In some preferred embodiments the present method is ented as batch process. Alterna—
, and sometimes preferably, the method may be implemented as semi—batch process. In
other preferred embodiments the method is implemented as a continuous process.
An advantage of the present method is that it is much faster than comparable methods for BLG
llisation of the prior art. The duration from the initial adjustment of the whey protein feed
to the completion of the separation of step c may be at most 10 hours, preferably at most 4
hours, more preferably at most 2 hours, and even more preferably at most 1 hour.
An additional aspect of the ion pertains to an isolated BLG crystal obtainable from the
method described herein.
In the context of the present ion the term ted BLG crystal” pertains to a BLG crystal
that has been separated from the on in which it was formed but which may still n
internal water, i.e. water ing BLG molecules of the crystal.
The isolated BLG crystal preferably has an orthorhombic space group P 21 21 21.
Preferably, the isolated BLG crystal has an orthorhombic space group P 21 21 21 and the unit cell
dimensions a=68.68 (i5%) A, b = 68.68 (i5%) A, and c = 156.65 (15%) A; and having the
unit cell integral angles a=90° (:|:2%), B=90° (:|:2%), and v=90° (:|:2%).
In some preferred embodiments of the invention, the isolated BLG crystal has an orthorhombic
space group P 21 21 21 and the unit cell dimensions a=68.68 (i2%) A, b = 68.68 (i2%) .3, and
c = 156.65 (12%) A; and has the unit cell integral angles a=90° (i1°/o), B=90° (i1°/o), and
v=90° (:l:1%).
Even more red the isolated BLG crystal may have an orthorhombic space group P 21 21 21
and the unit cell dimensions a=68.68 (i 1%) A, b = 68.68 (i1%) A, and c = 156.65 (:|:1%) A;
and have the unit cell integral angles a=90° (i0.5%), B=90° (i0.5%), and v=90° (i0.5%).
Most preferably the isolated BLG crystal has an orthorhombic space group P 21 21 21 and the
unit cell ions a=68.68 IA, b = 68.68 IA, and c = 156.65 A; and has the unit cell integral
angles o=90°, B=90°, and v=90°.
3O The isolated BLG crystal may e.g. se at least 20%(w/w) BLG and at most 80% (w/w)
water. Preferably, the isolated BLG crystal may comprise at least 40%(w/w) BLG and in the
range of 0—60% (w/w) water. Even more preferably, the isolated BLG crystal comprises in the
range of 40-60%(w/w) BLG and in the range of about 40 — about 60% (w/w) water
The present inventors have found that the BLG ls of the present invention surprisingly
have the ability to resume their original crystal structure after having been dried and rehydrat-
ed. This is particularly advantageous in applications which benefit from the crystal structure of
BLG.
RECTIFIED SHEET (RULE 91) ISA/EP
W0 2018!115520 2017/084553
Yet an aspect of the present invention pertains to an edible composition comprising beta-
lactoglobulin, e.g. an edible composition which is obtainable by the method as defined herein.
Another aspect of the invention pertains to an edible BLG composition comprising at least 90%
(w/w) BLG relative to total . Such an edible BLG composition may be obtainable by a
method as defined herein.
A further aspect of the invention pertains to an edible BLG composition comprising dried BLG
crystals, at least 20% (w/w) BLG ve to total solids, and preferably having a crystallinity
with respect to BLG of at least 20%. Such an edible BLG composition comprising dried BLG
crystals may be obtainable by a method as defined .
In some preferred embodiments of the invention the BLG of the edible BLG composition has a
degree of ylation of at most 1. Preferably, the BLG of the edible BLG composition has a
degree of lactosylation of at most 0.6. More preferably, the BLG of the edible BLG composition
has a degree of lactosylation of at most 0.4. Even more preferably, the BLG of the edible BLG
composition has a degree of lactosylation of at most 0.2. Most preferably, the BLG of the edible
BLG composition has a degree of lactosylation of at most 0.1, such as e.g. preferably at most
0.01.
In some preferred embodiments of the invention the BLG of the edible BLG composition com—
prises at least 90% (w/w) non—lactosylated BLG, preferably at least 95% (w/w) non—
lactosylated BLG, and even more preferably at least 98% (w/w) non—lactosylated BLG.
The percentage of non—lactosylated BLG is determined according to Example 9.1.
In some preferred ments of the invention the BLG of the edible BLG ition has a
crystallinity of at least 10% (w/w). Preferably, the BLG of the edible BLG composition has a
crystallinity of at least 20% (w/w). More ably the BLG of the edible BLG composition has
3O a crystallinity of at least 30% (w/w). Even more preferably the BLG of the edible BLG composi—
tion has a crystallinity of at least 40% (w/w).
Even higher crystallinities are often preferred. Thus, in some preferred embodiments of the
invention the BLG of the edible BLG composition has a llinity of at least 50% (w/w). Pref—
erably, the BLG of the edible BLG composition has a crystallinity of at least 60% (w/w). More
preferably, the BLG of the edible BLG ition has a crystallinity of at least 70% (w/w).
Even more preferably, the BLG of the edible BLG composition has a crystallinity of at least 80%
(w/w). Most preferred, the BLG of the edible BLG composition has a crystallinity of at least 90%
(w/w), and preferably at least 95% (w/w).
W0 2018!115520
The crystallinity of BLG in a liquid having pH in the range of 5—6 is measured according to Ex—
ample 9.7. The crystallinity of BLG in a powdered material is measured according to Example
9.8. If the edible composition is a dry product but no in the form a powder, it must be convert—
ed to a powder, e.g. by grinding or milling, before it is subjected to the method of Example 9.8.
In some preferred embodiments of the invention the edible BLG composition is a WPC, WPI,
SPC, or SPI, in which at least some of the BLG is on crystal form. The edible BLG composition
may e.g. comprise at most 90% (w/w) BLG relative to the total amount of protein, and has a
crystallinity of BLG of at least 10%. For e, the edible BLG composition may comprise at
most 80% (w/w) BLG ve to the total amount of protein, and have a crystallinity of BLG of
at least 10%. The edible BLG composition may e.g. comprise 30—70% (w/w) BLG ve to the
total amount of protein, and have a llinity of BLG of at least 10%.
In other preferred embodiments of the invention, the edible BLG composition comprises at most
90% (w/w) BLG relative to the total amount of protein, and have a crystallinity of BLG of at
least 30%. Preferably, the edible BLG composition may comprise at most 80% (w/w) BLG rela—
tive to the total amount of protein, and have a crystallinity of BLG of at least 30%. Even more
preferably, the edible BLG composition may comprise 30—70% (w/w) BLG relative to the total
amount of protein, and have a crystallinity of BLG of at least 30%.
The present inventors have found that the present ion makes it possible to prepare an
edible whey protein product having a very low content of orus and other minerals, which
is ageous for patients suffering from kidney diseases or otherwise having a reduced kid—
ney function.
The edible BLG composition is preferably a low phosphorus ition.
In the context of the present ion the term “low phosphorus” pertains to a composition,
3O e.g. a liquid, a powder or another food product, that has a total content of phosphorus of at
most 100 mg phosphorus per 100 g protein. Preferably, a low orus composition has a
total content of at most 80 mg phosphorus per 100 g protein. More preferably, a low phospho—
rus composition may have a total content of at most 50 mg phosphorus per 100 g protein. Even
more preferably, a low phosphorus composition may have a total content of phosphorus of at
most 20 mg phosphorus per 100 g protein. Even more ably, a low phosphorus composi—
tion may have a total content of phosphorus of at most 5 mg phosphorus per 100 g protein.
.Low orus compositions according to the present ion may be used as a food ingre—
dient for the production of a food product for patients groups that have a reduced kidney func—
tion.
W0 2018!115520
Thus, in some particularly preferred embodiments of the invention the edible BLG composition
comprises at most 80 mg phosphorus per 100 g protein. Preferably, the edible BLG ition
comprises at most 30 mg phosphorus per 100 g n. More preferably, the edible BLG com—
position comprises at most 20 mg phosphorus per 100 g protein. Even more ably, the
edible BLG composition comprises at most 10 mg phosphorus per 100 g protein. Most prefera—
bly, the edible BLG composition comprises at most 5 mg phosphorus per 100 g protein.
The content of phosphorus relates to the total amount of elemental phosphorus of the composi—
tion in question and is determined according to Example 9.5.
In other preferred embodiments of the invention the edible BLG composition is a low mineral
composition.
In the context of the present invention the term “low mineral” pertains to a composition, e.g. a
liquid, a powder or another food product, that has at least one, preferably two, and even more
preferably all , of the ing:
- an ash t of at most 1.2% (w/w) relative to total solids,
— a total content of calcium and magnesium of at most 0.3% (w/w) relative to total sol—
ids,
— a total content of sodium and potassium of at most 0.10% (w/w) relative to total sol—
ids,
— a total content of phosphorus of at most 100 mg phosphorus per 100 g protein.
ably, a low mineral composition has at least one, ably two or more, and even more
preferably all, of the following:
— an ash content of at most 0.7% (w/w) relative to total solids,
— a total content of calcium and magnesium of at most 0.2% (w/w) relative to total
solids,
— a total content of sodium and potassium of at most 0.08% (w/w) relative to total
solids,
— a total content of orus of at most 80 mg phosphorus per 100 g protein.
Even more preferably, a low mineral composition has at least one, preferably two or more, and
even more preferably all, of the ing:
— an ash t of at most 0.5% (w/w) relative to total solids,
W0 15520
— a total content of calcium and magnesium of at most 0.15% (w/w) relative to
total solids,
— a total content of sodium and potassium of at most 0.06% (w/w) relative to total
solids,
— a total content of phosphorus of at most 50 mg phosphorus per 100 g protein.
It is particularly red that a low mineral composition has the following:
— an ash content of at most 0.5 % (w/w) relative to total solids,
— a total content of calcium and ium of at most 0.15 % (w/w) relative to
total ,
— a total content of sodium and potassium of at most 0.06% (w/w) relative to total
solids,
— a total content of phosphorus of at most 50 mg phosphorus per 100 g protein.
In some preferred embodiments of the invention the edible BLG composition comprises a total
amount of protein of at least 25% (w/w) relative to the total solids of the edible BLG composi—
tion. Preferably, the edible BLG composition comprises a total amount of n of at least 50%
(w/w) relative to the total solids of the edible BLG composition. More preferred, the edible BLG
composition comprises a total amount of protein of at least 75% (w/w) relative to the total sol—
ids of the edible BLG composition. Even more preferred, the edible BLG composition ses
a total amount of protein of at least 90% (w/w) relative to the total solids of the edible BLG
composition.
In some preferred embodiments of the invention the total amount of protein of the edible BLG
composition is in the range of 25—100% (w/w) relative to total solids. Preferably, the total
amount of protein of the edible BLG composition is in the range of 50—100% (w/w). More pre—
ferred, the total amount of protein of the edible BLG composition is in range of 75—100% (w/w)
3O ve to total . Even more preferred, the total amount of n of the edible BLG com—
on is in the range of 90-100% (w/w) relative to total solids.
In some preferred embodiments of the invention the edible BLG composition comprises at least
75% (w/w) BLG relative to the total amount of n. Preferably, the edible BLG composition
may comprise at least 90% (w/w) BLG relative to the total amount of protein. More preferably,
the edible BLG composition may comprise at least 95% (w/w) BLG relative to the total amount
of protein. Even more preferably, the edible BLG composition may comprise at least 97% (w/w)
BLG relative to the total amount of protein. Most preferably, the edible BLG composition com—
prises approx. 100% (w/w) BLG relative to the total amount of protein.
W0 2018!115520 2017/084553
In some red ments of the invention the edible BLG composition contains at most
% (w/w) carbohydrate, preferably at most 5% (w/w) carbohydrate, more preferably at most
1% (w/w) carbohydrate, and even more preferably at most 0.1% (w/w) carbohydrate.
The edible BLG ition may also comprise lipid, e.g. in the form of triglyceride and/or oth—
er lipid types such as phospholipids.
In some embodiments of the invention the edible BLG composition comprises a total amount of
lipid of at most 1% (w/w) relative to total . Preferably, the edible BLG ition com—
prises a total amount of lipid of at most 0.5% (w/w) relative to total solids. More preferably, the
edible BLG composition comprises a total amount of lipid of at most 0.1% (w/w) relative to to—
tal solids. Even more preferably, the edible BLG composition comprises a total amount of lipid
of at most 0.05% (w/w) relative to total solids. Most preferably, the edible BLG composition
comprises a total amount of lipid of at most 0.01% (w/w) relative to total solids.
In some preferred ments of the invention the edible BLG composition is a dry composi—
tion, and e.g. a powder. It is particularly preferred that the edible BLG composition is a spray—
dried powder.
The present inventors have ed that edible BLG compositions in powder form in which at
least some of the BLG was in crystal form when dried have a higher density than comparable
BLG composition without BLG crystals (see Example 7). This high density effect is very surpris—
ingly also observed for edible BLG compositions in powder form which are obtained from spray-
dried BLG crystal slurries.
Thus, in some preferred embodiments of the invention the edible BLG composition in powder
form has a bulk density of at least 0.40 g/mL. Preferably the edible BLG composition in powder
form has a bulk density of at least 0.45 g/mL. More preferably the edible BLG composition in
powder form has a bulk density of at least 0.50 g/mL. It is even more preferred that the edible
3O BLG ition in powder form has a bulk density of at least 0.6 g/mL. The edible BLG com—
position in powder form may e.g. have a bulk density of at least 0.7 g/mL.
The age of bulk density both applies to powders of edible BLG compositions in which BLG
is nearly the only n present and to powders of edible BLG compositions wherein the con—
centration of BLG has not been enriched relative to the other proteins that were present in the
whey protein solution. The invention therefore provides high density powders of both isolated
BLG and crude whey protein, which comprises significant amounts of ALA and other whey pro—
teins in addition to BLG.
W0 2018!115520
In some preferred embodiments of the invention the edible BLG composition in powder form
has a bulk density of at least 0.45 g/mL and ses at least 70% (w/w) protein relative to
the total weight of the composition. More preferably the edible BLG composition in powder form
has a bulk density of at least 0.50 g/mL and comprises at least 70% (w/w) protein ve to
the total weight of the composition.. It is even more preferred that the edible BLG composition
in powder form has a bulk density of at least 0.6 g/mL and comprises at least 70% (w/w) pro—
tein relative to the total weight of the composition. The edible BLG ition in powder form
may e.g. have a bulk density of at least 0.7 g/mL and comprises at least 70% (w/w) protein
relative to the total weight of the composition.
In other preferred embodiments of the invention the edible BLG composition in powder form
has a bulk density of at least 0.45 g/mL and comprises at least 80% (w/w) protein relative to
the total weight of the composition. More preferably the edible BLG composition in powder form
has a bulk density of at least 0.50 g/mL and comprises at least 80% (w/w) n relative to
the total weight of the composition. It is even more preferred that the edible BLG composition
in powder form has a bulk density of at least 0.6 g/mL and comprises at least 80% (w/w) pro—
tein relative to the total weight of the composition. The edible BLG composition in powder form
may e.g. have a bulk density of at least 0.7 g/mL and comprises at least 80% (w/w) protein
relative to the total weight of the composition.
The edible BLG ition in powder form may e.g. have a bulk density in the range of 0.40—
1.5 g/mL and comprises at least 80% (w/w) protein relative to the total weight of the composi—
tion. ably, the powdered, edible BLG composition has a bulk density in the range of 0.45—
1.0 g/mL and comprises at least 80% (w/w) protein relative to the total weight of the composi—
tion. More preferably the powdered, edible BLG composition may have a bulk y in the
range of 0.50—0.9 g/mL and comprises at least 80% (w/w) protein relative to the total weight of
the composition. It is even more preferred that the powdered, edible BLG ition has a
bulk density in the range of 0.6—0.9 g/mL and comprises at least 80% (w/w) protein relative to
the total weight of the composition. The powdered, edible BLG composition may e.g. have a
3O bulk density in the range of 0.6—0.8 g/mL and comprises at least 80% (w/w) protein relative to
the total weight of the composition.
The inventors have found that the high density s of the invention advantageously allows
for more cost—effective packaging and logistics of the powder as less packaging material is re—
quired per kg powder and more powder (mass) can be transported by a given ner or
truck.
The edible BLG composition in powder form may e.g. have a bulk y in the range of 0.40—
1.5 g/mL. Preferably, the powdered, edible BLG composition has a bulk density in the range of
W0 2018!115520
0.45—1.0 g/mL. More preferably the powdered, edible BLG composition may have a bulk density
in the range of 0.50-0.9 g/mL. It is even more red that the powdered, edible BLG compo—
sition has a bulk y in the range of 0.6—0.9 g/mL. The powdered, edible BLG composition
may e.g. have a bulk y in the range of 0.6—0.8 g/mL.
In other preferred embodiments of the invention the edible BLG ition in powder form
has a bulk density in the range of 0.50—1.5 g/mL. ably, the ed, edible BLG compo—
sition has a bulk density in the range of 0.55—1.0 g/mL. More preferably the powdered, edible
BLG composition may have a bulk density in the range of 0.60—1.0 g/mL. It is even more pre—
ferred that the powdered, edible BLG composition has a bulk density in the range of O.65—1.0
g/mL. The powdered, edible BLG composition may preferably have a bulk density in the range
of 0.70-1.0 g/mL.
The edible BLG composition in powder form may e.g. have a bulk density in the range of 0.40-
1.5 g/mL and comprises at least 70% (w/w) protein relative to the total weight of the composi—
tion. Preferably, the ed, edible BLG composition has a bulk density in the range of 0.45-
1.0 g/mL and comprises at least 70% (w/w) protein relative to the total weight of the composi—
tion. More preferably the powdered, edible BLG composition may have a bulk density in the
range of 0.50—0.9 g/mL and comprises at least 70% (w/w) protein relative to the total weight of
the composition. It is even more preferred that the powdered, edible BLG composition has a
bulk density in the range of 9 g/mL and comprises at least 70% (w/w) protein relative to
the total weight of the composition. The powdered, edible BLG composition may e.g. have a
bulk density in the range of 0.6—0.8 g/mL and comprises at least 70% (w/w) protein relative to
the total weight of the composition.
The edible BLG composition in powder form may e.g. have a bulk density in the range of 0.40—
1.5 g/mL and comprises at least 80% (w/w) protein relative to the total weight of the composi—
tion. Preferably, the powdered, edible BLG ition has a bulk density in the range of 0.45—
1.0 g/mL and comprises at least 80% (w/w) protein relative to the total weight of the composi—
3O tion. More preferably the powdered, edible BLG composition may have a bulk density in the
range of 0.50-0.9 g/mL and ses at least 80% (w/w) protein ve to the total weight of
the composition. It is even more preferred that the powdered, edible BLG composition has a
bulk density in the range of 0.6-0.9 g/mL and comprises at least 80% (w/w) protein relative to
the total weight of the composition. The powdered, edible BLG composition may e.g. have a
bulk density in the range of 0.6—0.8 g/mL and comprises at least 80% (w/w) protein relative to
the total weight of the composition.
In other red embodiments of the invention the edible BLG composition in powder form
has a bulk density in the range of 0.50—1.5 g/mL and comprises at least 70% (w/w) protein
W0 2018!115520
relative to the total weight of the composition. Preferably, the powdered, edible BLG i—
tion has a bulk density in the range of 0.55-1.0 g/mL and comprises at least 70% (w/w) protein
relative to the total weight of the composition. More preferably the powdered, edible BLG com—
position may have a bulk density in the range of 0.60—1.0 g/mL and comprises at least 70%
(w/w) protein relative to the total weight of the composition. It is even more preferred that the
powdered, edible BLG composition has a bulk y in the range of 0.65—1.0 g/mL and com—
prises at least 70% (w/w) protein relative to the total weight of the composition. The powdered,
edible BLG composition may preferably have a bulk density in the range of .0 g/mL and
comprises at least 70% (w/w) protein relative to the total weight of the composition.
In other preferred ments of the ion the edible BLG composition in powder form
has a bulk density in the range of 0.50—1.5 g/mL and ses at least 80% (w/w) protein
relative to the total weight of the composition. Preferably, the powdered, edible BLG composi—
tion has a bulk density in the range of 0.55-1.0 g/mL and comprises at least 80% (w/w) protein
relative to the total weight of the composition. More preferably the powdered, edible BLG com—
position may have a bulk y in the range of 0.60—1.0 g/mL and comprises at least 80%
(w/w) protein relative to the total weight of the composition. It is even more preferred that the
powdered, edible BLG composition has a bulk density in the range of 0.65—1.0 g/mL and com—
prises at least 80% (w/w) protein relative to the total weight of the composition. The powdered,
edible BLG composition may preferably have a bulk y in the range of O.70-1.0 g/mL and
ses at least 80% (w/w) protein relative to the total weight of the composition.
The bulk density of a powder is measured according to Example 9.3.
The present ors have seen indications that the BLG compositions according to the present
invention have better long—term stability than similar BLG compositions. This is particularly the
case when at least some of the BLG is present in the form of BLG crystals, which seem to offer
a better storage stability of the BLG molecules.
3O In some preferred embodiments of the invention the dry BLG composition has a furosine value
of at most 80 mg/100 g protein after 60 days at 30 degrees C, preferably at most 60 mg/100 g
protein, more preferably at most 40 mg/100 g protein, and even more preferably at most 20
mg/100 g protein. Most ably, the dry BLG composition has a furosine value of at most 10
mg/100 g protein after 60 days at 30 s C.
In some preferred embodiments of the invention the dry BLG composition has a furosine value
of at most 80 mg/100 g n, preferably at most 60 mg/100 g protein, more preferably at
most 40 mg/100 g protein, and even more preferably at most 20 mg/100 g protein. Most pref—
W0 2018!115520
, the dry BLG composition has a furosine value of at most 10 mg/100 g protein. Prefera—
bly the dry BLG composition has a furosine value of 0 mg/100 g protein.
In some preferred embodiments of the invention the BLG of the dry BLG composition has a de—
gree of lactosylation of at most 1 after 60 days at 30 degrees C, preferably at most 0.6, more
preferably 0.2, even more preferably at most 0.1, and most preferably at most 0.01.
In some preferred embodiments of the ion the edible BLG composition is a liquid compo—
sition. A liquid edible BLG composition preferably comprises at least 20% (w/w) water, more
preferably at least 30% (w/w) water, even more preferably at least 40% (w/w).
The liquid edible BLG composition may e.g. ses in the range of 20—90% (w/w) water,
more preferably in the range of 30—80% (w/w) water, even more preferably at least 40%
(w/w).
The present inventors have found that edible BLG compositions according to the present inven-
tion have singly low degree of protein denaturation, even spray—drying has been used to
e an edible BLG powder composition (see e 11).
Thus, in some preferred embodiments of the invention the edible BLG composition has a degree
of protein denaturation of at most 2%. ably, the edible BLG composition has a degree of
protein denaturation of at most 1.5%. More preferably, the edible BLG composition has a de—
gree of protein denaturation of at most 1.0%. Even more preferably, the edible BLG composi—
tion has a degree of n denaturation of at most 0.8%. Even more preferably, the edible
BLG composition has a degree of protein denaturation of at most 0.5%.
In some preferred embodiments of the invention, the edible BLG composition is a dry powder,
and preferably a spray—dried powder, and has a degree of protein denaturation of at most 2%,
and preferably at most 1.5%. More preferably, the dry edible BLG composition, e.g. in the form
3O of a spray—dried powder, has a degree of protein denaturation of at most 1.0%. Even more
preferably, the dry edible BLG composition, e.g. in the form of a dried powder, has a de—
gree of protein denaturation of at most 0.8%. Even more preferably, the dry edible BLG compo—
sition, e.g. in the form of a spray-dried , has a degree of protein denaturation of at most
0.5°/o.
In some preferred embodiments of the invention, the edible BLG composition comprises:
- At most 6% (w/w) water
- At least 80% total protein relative to total solids
— At least 95% BLG relative to total protein, and
W0 2018!115520
said edible BLG composition:
- Is a dry powder, and
— Has a bulk density of at least 0.50 g/mL, and preferably at least 0.60 g/mL.
In other preferred embodiments of the invention, the edible BLG composition ses:
- At most 6% (w/w) water
— At least 80% total protein relative to total solids
- At least 95% BLG relative to total protein, and
said edible BLG composition:
- Is a dry powder,
— Has a bulk density of at least 0.50 g/mL, and preferably at least 0.60 g/mL, and
- Has a crystallinity of BLG of at least 20% and preferably at least 40%.
In further preferred embodiments of the invention, the edible BLG composition comprises:
— At most 6% (w/w) water
— At least 80% total n relative to total solids
- At least 95% BLG ve to total n, and
said edible BLG composition:
- Is a dry powder,
— Has a bulk density of at least 0.50 g/mL, and preferably at least 0.60 g/mL, and
- Has a degree of protein denaturation of at most 2%, and preferably at most 1.0%.
In further preferred embodiments of the invention, the edible BLG composition comprises:
- At most 6% (w/w) water
— At least 80% total protein relative to total solids,
— At least 95% BLG relative to total protein,
- at most 80 mg phosphorus per 100 g protein.
said edible BLG composition:
— Is a dry powder.
In yet preferred ments of the ion, the edible BLG composition comprises:
- At most 6% (w/w) water
- At least 90% total protein relative to total solids,
— At least 97% BLG relative to total protein,
- at most 50 mg phosphorus per 100 g protein.
said edible BLG composition:
- Is a dry powder.
W0 2018!115520
In other preferred embodiments of the invention, the edible BLG ition comprises:
- At most 6% (w/w) water
— At least 80% total protein relative to total solids, and preferably at least 90% total pro—
tein relative to total solids,
— 30—70% BLG relative to total protein,
— 8—25% (w/w) ALA relative to total protein,
said edible BLG composition:
- Is a dry powder, and
— Has a crystallinity of BLG of at least 20% and preferably at least 40%.
In some preferred embodiments of the invention, the edible BLG composition ses:
- 20-80% (w/w) water, and preferably 20-60% (w/w) water,
- At least 80% total n ve to total solids, and preferably at least 90% total pro—
tein
- At least 95% BLG relative to total protein,
— at most 80 mg phosphorus per 100 g protein.
said edible BLG ition:
— has a llinity of BLG of at least 20%, preferably at least 40,and
- optionally, has a degree of protein denaturation of at most 2%, and preferably at most
1.0%.
Edible compositions according to these embodiments are particularly useful for preparing edible
BLG compositions in dried form, and are particularly suitable for spray-drying and preparation
of a high density whey protein powder having the normal concentration profile of whey protein
species whey protein but containing at least some of the BLG in the form of dried BLG crystals.
In other preferred embodiments of the invention, the edible BLG composition comprises:
- 20—80% (w/w) water, and preferably 20—60% (w/w) water,
— At least 80% total protein relative to total solids, and preferably at least 90% total pro—
tein relative to total solids,
— 30—70% BLG ve to total protein,
— 8—25% (w/w) ALA ve to total protein,
said edible BLG composition:
- Has a crystallinity of BLG of at least 20% and ably at least 40%.
Edible compositions according to these embodiments are particularly useful for preparing edible
BLG compositions in dried form, and are particularly suitable for spray—drying and preparation
of a high density whey protein powder having the normal concentration profile of whey protein
species whey protein but containing at least some of the BLG in the form of dried BLG crystals.
W0 2018!115520
Yet an aspect of the invention pertains to the use of an edible BLG ition as defined here—
in as a food ingredient.
It may for example be preferred to use a low phosphorus, edible BLG composition as defined
herein as a food ingredient in the production of a low phosphorus food product.
A further aspect of the invention ns to a food t comprising an edible BLG composi—
tion as d herein and at least an additional ingredient, such as e.g. a source of fat and/or
carbohydrate.
In some preferred ments of the invention the food product is a dry food product, e.g. a
bar, comprising carbohydrate and protein, said dry food product comprising at least 1% (w/w)
BLG, preferably at least 5%, wherein:
i) the crystallinity of BLG is at least 20%, preferably at least 40%, and/or
ii) at least 90% (w/w) of the total amount of protein is comprised by BLG.
In some particularly preferred embodiments of the invention the food t is a low phospho—
rus food t comprising at most 100 mg phosphorus per 100 g protein, preferably at most
80 mg phosphorus per 100 g protein, more preferably at most 40 mg phosphorus per 100 g
protein, and even more ably at most 20 mg phosphorus per 100 g protein.
BLG has a favourable amino acid profile and preferably contributes with a significant part of the
protein of the food product. This is particularly interesting if the food product is a low mineral or
low phosphorous food product. In some preferred embodiments of the invention the edible BLG
composition contributes to at least 25% (w/w) of the total amount of protein of the food prod—
uct, or at least 50% (w/w), more preferably at least 80% (w/w), and even more preferred at
least 90% (w/w). It may even be most preferred that the edible BLG composition contributes
with all protein of the food t.
3O In some red embodiments of the invention the low phosphorus, edible BLG composition
contributes to at least 25% (w/w) of the total amount of protein of the low phosphorus food
product, or at least 50% (w/w), more preferably at least 80% (w/w), and even more preferred
at least 90% (w/w). It may even be most preferred that the low phosphorus, edible BLG com-
position contributes with all n of the low phosphorus food product.
Non—limiting examples of the food product are e.g. a dairy product, a candy, a beverage, a pro—
tein bar, an enteral nutritional composition, a bakery product.
W0 2018!115520
In some preferred embodiments of the invention the food product is a beverage. The beverage
preferably ses:
— an edible BLG composition as defined herein to provide at total amount of BLG of at least 1%
(w/w), preferably at least 5% (w/w), more preferably at least 8% (w/w), and even more pref—
erably at least 12% (w/w),
— a sweetener, e.g. a sugar sweetener and/or a gar sweetener,
- at least one food acid, e.g. citric acid or other suitable food acids,
— optionally, a ring agent, and
— at most 80 mg orus/100 g protein
which has a pH in the range of 0.
The present inventors have realised that the preparation of acidic, high protein, low mineral,
beverages or liquid from dry edible BLG composition comprising BLG crystals is not trivial. The
dry edible BLG composition sing BLG crystals typically create a pH in the range 5—6 when
resuspended in water and addition of acids or salts to change the pH or increase the conductivi-
ty also increases the mineral load of the resulting /beverage.
However, the inventors have found that if a ylic acid, a lactone, a carboxylic acid anhy—
dride, or a combination thereof are used to lower the pH no unnecessary minerals are added
and a better control of the mineral composition of the beverage/liquid is obtained.
Thus an aspect of the invention pertains to a process of producing an acidified, low mineral liq—
uid using an edible BLG composition comprising BLG crystals as an ingredient, the method
comprising the steps of:
— providing one or more acidifying agent(s) selected from the group consisting of a car—
boxylic acid, a lactone, a carboxylic acid anhydride, or a combination thereof,
- contacting the edible BLG composition comprising BLG crystals with the one or more
acidifying agent(s), and optionally onal ingredients such as e.g. water, a fat
source and/or a carbohydrate , said one or more acidifying agent(s) used in an
amount sufficient to adjust the pH to 2—4.5, and preferably 0, and allowing the
BLG crystals to dissolve
thereby forming the liquid.
The liquid may e.g. be used as a beverage or it may be used as an ingredient for producing
another food product.
W0 2018!115520
If the edible BLG composition used in the process is provided in dry form, e.g. as a powder, it is
often preferred to allow it to rehydrate in water before adding the acidifying agent.
The edible BLG ition used in the process is preferably present in the liquid in an amount
sufficient to provide 1—30% (w/w) protein, preferably 2—25% (w/w) protein, more preferably 4—
% (w/w) protein, and even more preferably 5—16% (w/w) protein.
The edible BLG composition used in the process preferably has a crystallinity of BLG of at least
%, preferably at least 50% and even more preferably at least 70%.
Examples of suitable acidifying agent(s) are:
— ylic acids such as e.g. acetic acid, maleic acid, tartaric acid, lactic acid, citric acid, glu—
conic acid, or mixtures thereof,
- lactones such as e.g. ono—delta—lactone,
- carboxylic acid anhydrides.
In some preferred embodiments the edible BLG composition comprising BLG ls used in
the process is preferably a low phosphorus ition and any other ingredients used in the
process are preferably selected so the final liquid also is a low phosphorus composition.
In other preferred embodiments the edible BLG composition comprising BLG crystals used in
the process is preferably a low mineral composition and any other ingredients used in the pro—
cess are ably chosen so that the final liquid also is a low mineral composition.
The process is preferably performed at a temperature in the range of 1—65 degrees C, prefera—
bly 2-50 s C, more ably in the range of 3—20 degrees C, even more preferably in
the range of 4—15 degrees C.
The present invention has been bed above with reference to specific embodiments. How—
ever, other embodiments than the above described are equally possible within the scope of the
3O invention. The different features and steps of various embodiments and aspects of the invention
may be combined in other ways than those described herein unless it is stated otherwise.
Example 1: Crystallization of beta-lactoglobulin from a crude whey protein concen-
trate
W0 2018!115520
Lactose depleted UF retentate derived from sweet whey from a standard cheese production
process and filtered through a 1.2 micron filter was used as feed for the BLG crystallization pro—
cess. The sweet whey feed was conditioned on an ultrafiltration setup using a Koch 8
type membrane with a 46 mil spacer feed pressure of 1.5—3.0 bar, using a feed concentration of
21% TS (total solids) i5, and ed water (water filtered by reverse osmosis to obtain a
conductivity of at most 0.05 mS/cm) as diafiltration medium. The temperature of the feed and
retentate during ultrafiltration was approx. 12 degrees C. The pH was then adjusted by adding
HCI to obtain a pH of approx. 5.40. Diafiltration continued until the drop in tivity of the
retentate was below 0.03 mS/cm over a 20 min period. The retentate was then concentrated to
approx. 30% TS (approx. 23.1% total protein relative to the total weigh of the trated
retentate). A sample of the trated retentate was centrifuged at 3000 g for 5 minutes but
no visible pellet was formed. The supernatant was subjected to HPLC analysis. The composition
of the feed is shown in Table 1.
The concentrated retentate was seeded with 0.5 g/L pure BLG crystal material obtained from a
spontaneous BLG crystallization (as described in Example 3 in the context of feed 2). The seed-
ing material was prepared by washing a BLG crystal slurry 5 times in milliQ water, collecting the
BLG crystals after each wash. After washing, the BLG crystals were freeze dried, grounded up
using a pestle and , and then passed through a 200 micron sieve. The crystallization
seeds therefore had a particle size of less than 200 micron.
The concentrated retentate was erred to a 300L crystallization tank where it was cooled to
about 4 degrees C and kept at this temperature overnight with gentle stirring. Next morning, a
sample of the cooled concentrated retentate was transferred to a test tube and inspected both
visually and microscopy. Rapidly sedimenting crystals had clearly formed overnight. A lab sam—
ple of the mixture comprising both crystals and mother liquor was further cooled down to 0
degrees C in an ice water bath. The mother liquor and the ls were separated by centrifu—
3O gation 3000 g for 5 minutes, and samples of the supernatant and pellet were taken for HPLC
analysis. The crystals were washed once in cold polished water and then fuged again be—
fore freeze—drying the pellet.
Table 1 Concentration of selected ents of the feed standardized to 95% (w/w) total .
Feed standardized to 95% TS
Q Protein composition (% w/w relative to
total protein)
ALA 17.7":
BLG 51.6
CMP 19.5.;
H'Other components (% W/w relative to total M
weight of the standardized feed)
Ca O . 357
K 0.200'
WMg 0.058,,
{Na _. 0.045.
"rs 0.280,
:wath ._
.6,
____p_,rotem VVVVVVVVVVVVVV . 79.-.,
BLG relative yield quantification by HPLC:
All samples were subjected to the same degree of dilution by adding polished water. The sam—
ples were filtered through a 0.22 micron filter. For each sample the same volume was loaded on
an HPLC system with a Phenomenex Jupiter® 5 pm C4 300 A, LC Column 250 x 4.6 mm (Part
Number:00G—4167-EO) and detected at 214 nm.
The samples were run using the following conditions:
Buffer A: MilliQ water, w TFA
Buffer B: HPLC grade acetonitrile, 0.085%w/w TFA
Flow: lml/min
Gradient: 0-30 minutes A and 18-45%B; 30-32 minutes 55-10%A and 45-90%B; 32.5-
37.5 minutes 10%A and 90%B; 38-48 minutes A and 90—18%B.
Data treatment:
As all samples were treated in the same way, we can directly compare the area of the BLG
peaks to gain a relative yield. As the crystals only contain BLG and the samples all have been
d in the same way, the concentration of alpha—lactalbumine (ALA) and hence the area of
ALA should be the same in all of the samples, ore the area of ALA before and after crys—
tallization is used as a correction factor (cf) when calculating the relative yield.
area 01: ALAbefore
crystallization
Cf“ =
area of ALA
after crystallization
W0 2018!115520
The relative yield is calculated by the following equation:
( Cfa X area of BLGafter crystallization
Yield = 1 — X 100
area of BLG
before crystallization
Results:
Figure 1 shows the overlaid chromatograms from before and after crystallization of BLG from a
sweet whey. The “before crystallization” sample is represented by the solid black line and the
“after crystallization” sample by the dotted line. It is apparent that a large decrease in the con—
centration of BLG has occurred, and using the yield calculation as previously bed the yield
of removed BLG was determined to 64.5% (w/w).
The crystal slurry was investigated by microscopy; as can be seen from Figure 2, the sample
contained nal ls, many having a size considerably larger than 200 micron indicat—
ing that the observed crystals are not only the seeding crystals. The crystals easily shattered
when pressed with a needle which confirmed that they were protein crystals.
Figure 3 shows the chromatogram of a washed crystal product, and in this case BLG makes up
98.9% of the total area of the togram. The purity of the BLG product can be increased
even further by onal washing.
Conclusion:
This example demonstrates that surprisingly it is possible to lize BLG selectively from a
crude whey protein concentrate which contains more that 48% non—BLG protein relative to total
protein and that the obtained BLG crystal isolate has an extremely high purity. This discovery
opens up for a new approach for industrial milk protein separation, in which BLG is separated
from the other protein components in a gentle way that preferably avoids ed exposure to
high temperatures and problematic chemicals.
Example 2: The influence of conductivity and temperature on the yield of BLG
Protocol:
Using the same feed, experimental and analytical setup as in Example 1, s of the reten—
tate (approx. 13.9% (w/w) total protein) were taken during UF diafiltration at ent conduc-
tivity levels in order to investigate the influence of conductivity on the yield of BLG crystals. The
samples were cooled down to 4 degrees C and kept at this temperature overnight (however,
the inventors have observed that 30 s or even less may be sufficient for equilibrium to
be reached) and then three of the samples were cooled down to 0 degrees C in ice water and
W0 2018!115520
kept at this temperature for at least 1 hour to show the effects of temperature on yield. Results
for the 4 degrees C samples can be seen in Figure 4.
After the diafiltration was complete, samples were taken at Brix 21, 24 and 32.5 during concen—
tration. These samples were first cooled to 4 degrees C and kept at this temperature overnight.
The yield of BLG crystals was measured as described in Example 1. The samples were then
cooled down to 0 degrees C in ice water and kept at this temperature for at least 1 hour. Sub—
sequently, the yield of BLG crystals was measured again.
Results:
When plotting the relative yield of BLG vs. the conductivity in the samples as seen in Figure 4
there is a clear correlation between lower conductivity and higher relative yield of BLG.
In Figure 5, the yield of three of the samples varying in conductivity are shown at two tempera-
tures (4 and 0 degrees C), it can be seen that the lower the temperature, the greater the yield
of BLG. Lowering the temperature even further is expected to increase the yield.
Figure 6 shows the influence of the protein concentration on the relative yield of BLG both at 4
and 0 degrees C. The figure shows a clear correlation between the protein concentration, shown
here through a Brix measurement, and the ve yield of BLG, indicating that the ve
yield continues to increase as the protein tration increases.
Conclusion:
The ors have observed that a number of parameters impact the efficiency of the crystalli—
zation process. At a given pH value the yield of BLG can be increased by decreasing the conduc—
tivity, increasing the concentration of BLG, and decreasing the temperature.
e 3: Crystallisation of BLG in three types of whey protein ons
Protocol:
Using the same experimental and analytical setup as in Example 1, three different types of
whey protein—containing raw material were tested as feeds for llization. However, no
seeding was used in the experiment performed with feed 2. Feed 1 and 2 were based on sweet
whey and had been fat—reduced via a Synder FR membrane prior to ent as described in
Example 1. Feed 3 was derived from an acid whey.
The composition of the three feeds can be seen below in Table 2, Table 3, and Table 4. Feed 3
was lized at 21% TS (total protein of 13.3% w/w relative to the total weight of the feed),
W0 2018l115520 2017/084553
a significantly lower concentration than the other two (total n of 26.3% (w/w) in feed 1
and 25.0% (w/w) in feed 2).
The slurry of the crystallized feed 1 was centrifuged on a Maxi—Spin filter with a 0.45 micron CA
membrane at 1500 g for 5 minutes then 2 volumes of MilliQ water was added to the filter cake
before it was centrifuged again. The resulting filter cake was analyzed by HPLC. A photo of the
Maxi—Spin filter holding the pellet (filter cake) of the crystallized feed 1 is shown in Figure 24.
The pellet from feed 2 was washed with 2 volume MilliQ water and centrifuged again under
standard conditions before the pellet was analyzed by HPLC. The pellet from feed 3 was ana—
lyzed t washing.
Crystals made from feed 2 were diluted to 10%TS and pH adjusted to pH 7 using 1M NaOH to
reverse the crystallization. NaCl was added to a crystal slurry from feed 2, 36%TS to reverse
the crystallization.
Table 2 The concentration of selected components of feed 1 (whey protein concentrate based on
sweet whey). BDL= below detection limit in wet sample
Feed 1 (standardized to 95% TS)
Protein composition (% w/w relative to
total protein)
ALA 23.0
BLG 55.1
CMP 20.5
Other components (% w/w relative to the
total weight of the standardized feed)
Ca 0.387
K 0.290
Mg 0.066
Na 0.068
P 0.207
Fat BDL
protein tration
Table 3 The concentration of ed components of feed 2 (ALA-reduced whey protein concentrate
based on sweet whey). BDL= below detection limit in wet, non-standardized sample.
Feed 2 standardized to 95% T5
Protein composition (% w/w relative to
total protein)
W0 2018!115520
Other components (% w/w ve to the
total weight of the standardized feed)
3 LD
protein concentration
Table 4 The concentration of selected components of feed 3 (whey protein concentrate based on
acid whey).
Feed 3 standardized to 95% TS
Protein composition (% w/w relative to
total protein)
ALA 24.0
BLG 63.6
Other whey proteins 12.4
Other components (% w/w relative to the
total weight of the standardized feed)
Ca 0.205
K 0.051
Mg 0.013
Na 0.108
P 0.240
fat 9"
n concentration \I \Di—I
Feed 1:
In Figure 7, chromatograms of the protein composition of the feed (solid line) and the mother
liquor (dashed line) can be seen. It is evident that a large portion of BLG was recovered as
crystals by the process. The yield (calculated as described in example 1) of isolated BLG is ap—
prox. 65% relative to the total amount of BLG in the feed.
W0 15520
Figure 8 is a microscope photo of a sample taken during the early stages of the llization
period. Figure 9 is a microscope photo of a sample which was taken when the crystallization
had ended. It is clear from these two pictures that the BLG crystals are relatively fragile. Some
of the crystals appear to break during stirring and are converted from nal or c
shape to crystals fragment which still appear very compact and well—defined but have more
irregular shapes.
Figure 10 shows the togram of the BLG crystals which was separated and washed on a
spin filter. As seen on the figure the purity is very high and the removal of other whey proteins
is extremely efficient.
Feed 2:
In Figure 11 the protein composition of feed 2 (solid line) and the obtained mother liquor
(dashed line) can be seen. It is evident that a large portion of BLG has been removed, and the
ated yield was 82% relative to the total amount of BLG in the feed 2.
Figure 12 shows feed 2 before (left—hand picture) and after (right—hand picture) crystallization.
During crystallization the feed transformed from a transparent liquid (in which the stirring mag-
net was visible) to a milky white, opaque liquid.
Figure 13 shows a microscope photo of the BLG crystals. Hexagonal shapes can be seen though
the majority of the crystals are fractured.
Figure 16 is the chromatogram of the isolated pellet of BLG ls after being washed with 2
volumes of MilliQ water. The chromatogram clearly shows that the crystals contain BLG in a
very high .
3O Figures 14 and 15 show the results of either raising the conductivity (by adding NaCl) or alter—
ing the pH (by adjusting the pH to 7 by addition of NaOH) so that the nment no longer
favours the crystalline structure. In both cases the milky white suspension turns in to a trans—
parent liquid as the BLG crystals are dissolved.
The mineral composition of the crystal preparation obtained from feed 2 is provided in Table 5.
We note that the phosphorus to protein ratio was very low which makes the crystal preparation
suitable as a protein source for patients having kidney diseases.
Table 5 The concentration of selected components in the crystal preparation ed from feed 2.
Composition of the crystal preparation obtained % w/w relative to the composition standardized
from feed 2 to 95% TS
Total protein 93.4
Feed 3:
In Figure 17 chromatograms of the protein composition of feed 3 (solid line) and the resulting
mother liquor (dashed line) are shown. It is evident that a large portion of BLG was isolated (a
calculated yield of 70.3% relative to the total amount of BLG in the feed). If the protein content
had been higher before crystallization, the obtained yield would have been even higher.
Figure 18 is a microscope photo of the BLG ls isolated from feed 3 (substantially free of
CMP). The crystals had a rectangular shape as d to hexagonal. The rectangular crystals
seemed more robust than the nal ones. Figure 19 shows a chromatogram of the isolated
crystal pellet without g; the chromatogram clearly shows that the ls were BLG
crystals despite having a rectangular shape instead of a hexagonal shape (compare e.g. the
rectangular crystal shapes of Figure 18 with the hexagonal crystal shapes of Figure 2).
Table 6 The concentration of selected components of the crystal preparation obtained from feed 3.
from feed 3 ration standardized to 95% TS
Ca 0.103
K BDL
Mg 0.006
Na 0.035
P 0.041
Total protein 90
W0 2018l115520
The crystal ation derived from feed 3 contained 45 mg P/100 g protein. We note that the
phosphorus to protein ratio is very low, which makes the crystal preparation suitable as a pro—
tein source for patients having kidney diseases.
Conclusion:
All three feeds were suitable for the BLG crystallization process. The BLG crystals were easily
dissolved by adding salt or raising the pH or the ature. The new method makes it possi—
ble to prepare BLG preparations with very low contents of phosphorus, which makes the prepa—
rations suitable as a protein sources for patients having kidney diseases.
Example 4 The influence of pH on the BLG crystal yield
Protocol:
The same ol and experimental set up as Example 1 (using fat—reduced sweet whey pro—
tein concentrates) was used, with the exception that pH was adjusted to the levels bed in
Table 8 for each of the ments. The protein concentration at the beginning of the crystalli—
zation step was approx. 24% (w/w).
The pH was adjusted with either a thin NaOH solution (>4%) or a thin HCI ) solution in
order to investigate the impact of pH on the crystallization process and the obtained yield. After
crystallization, the BLG crystals were separated by centrifugation as described in Example 1.
Table 7 The concentration ranges of selected components of the feeds used for example 4.
Used feeds standardized to 95% T5
Protein composition % of total protein (%)
ALA 10-15
BLG 60-70
CMP 12—17
Other components (% w/w relative to the
total weight of the standardized feed)
Fat BDL
protein concentration
2017/084553
Table 8 Target pH of the samples
Results:
The yields were ated as described in Example 1. It should be noted that the starting sam—
ples were taken before addition of the seeding material. Therefore, if the samples were not su-
persaturated with respect to BLG, the seeding material would dissolve and contribute to the
total BLG concentration, in which case the BLG yield would appear to be negative.
Table 9 calculated yields of the samples base on HPLC measurements.
Yield of total BLG (0/0)
_ sample pH
1 4.84 -2.7
12 5.20 50.0
3 5.44 82.0
""4 5.73 62.1
5.93 40.9
6 6.12 -1.6
Conclusion:
This experiment demonstrates that crystallization of BLG in the g—in mode was possible in
the pH range of 5—6.
Example 5: Investigating the impact of increasing levels of conductivity
Protocol:
The same protocol and experimental set up as in Example 1 was used with the exception that
samples were taken at ent conductivities. The raw material shown in Table 10 was condi—
tioned and used as feed for the crystallization process. Before UF, samples of the raw material
were taken and NaCl was added in order to increase the conductivity, and to investigate under
which tivity levels BLG crystals were able to grow. The protein content during crystalliza—
tion was approx. 16.7% (w/w).
W0 2018!115520
Table 10 Composition ranges of the feeds used in Example 5.
Used feed standardized to 95% T5
Protein composition (% w/w relative to
total protein)
Other components (% w/w ve to the
total weight of the standardized feed)
n concentration
Results:
Samples were treated as described in Example 1. Figure 20 shows the calculated yields at dif—
ferent conductivities in the retentate. The point at 3.53 mS/cm was the raw material after pH
adjustment. All points above 3.53 were a result of adding NaCl to increase the conductivity. The
points below 3.53 were a result of tration on the UF system. The yield at 4.93 mS/cm was
close to zero was not deemed significant.
The retentate sample which had a conductivity of 4.93 mS/cm had a UF permeate conductivity
of approx. 5.7 mS/cm. The retentate sample having conductivity of 3.53 mS/cm had a UF per—
meate conductivity of approx. 4.35 mS/cm.
From Figure 20, it can be seen that BLG crystals were formed in the feed at conductivities be-
low 4.93mS/cm (at 4 degrees C and a total protein t of approx. 16.7% (w/w)). At a con—
ductivity in the retentate of approx. 2 mS/cm and the UF permeate conductivity of approx.
1.6mS/cm a BLG yield of approx. 75% was obtained.
Figure 21 is a cope photo of the ls formed at 4.20 mS/cm in the retentate showing
the expected BLG crystal characteristics.
Conclusion:
W0 2018l115520
The specific feed of Example 5 made it possible to form BLG crystals below 4.93 mS/cm (corre—
sponding to a UF permeate conductivity 5.75 mS/cm and a ratio between the conductivity and
the total amount of protein of 0.057). It is expected that the upper limit of the conductivity
s on the protein tration and the protein composition. For example, a higher pro—
tein tration and/or an increased content of the highly charged proteins or other macro—
molecules (e.g. CMP) are ed to raise the upper limit of the conductivity by which BLG
crystallization is possible.
Example 6: Crystallising BLG in a serum n concentrate
A serum protein concentrate (SPC) was ed by subjecting a skimmed milk to microfiltra—
tion using a Synder FR membrane and a process temperature of . 50 degrees C. The
obtained retentate contained substantially all of the casein and residual fat and furthermore
contains some serum protein, lactose and minerals. The permeate contained molecules that
were capable of permeating through the membrane including serum protein, lactose and miner—
al, but substantially no casein or fat. The permeate was then prepared for crystallization as
described in Example 1 (see Table 11 for the composition of the feed) and the obtained BLG
crystals were characterised as described in Example 1. However, instead of performing all UF
operations at 12 degrees C, the ature of the retentate was increased from 12 to 25 de—
grees C when the conductivity of the retentate approached 1 mS/cm. The ature was
increased to avoid spontaneous crystallisation of BLG during UF concentration.
Table 11 The concentration of selected components of the feed (serum n concentrate). BDL=
below detection limit in wet, andardized sample.
Feed standardized to 95% TS
Protein composition (% w/w relative to
total protein)
ALA 23.5
BLG 66.7
Other whey proteins
Other components (% w/w relative to the
total weight of the standardized feed)
K BDL
Na BDL
Fat BDL
protein concentration
W0 2018!115520
Similar to the crystallisations of Examples 1-5, the BLG of the SPC feed formed crystals that
could be separated in very high purity (confirmed by chromatography as in the previous exam—
ples) and provided a yield of BLG of 70% relative to the total amount of BLG of the SPC feed. In
Figure 22, BLG crystals from the early stages of the crystallization are shown. As seen previous—
ly, the crystals have a rectangular or square shape as d to the hexagonal shape ob-
served e.g. in Example 2.
Example 7: Preparation of spray-dried BLG ls and determination of bulk density
A portion of the BLG cwstals produced in Example 3 (using feed 2) was separated on a decant—
er fuge at 1200 g, 5180 RPM, 110 RPM Diff. with a 64 mil spacer (mil means 1/1000 inch)
and a flow of 25—30 L/h. The BLG crystal phase was then mixed 1:1 with polished water and
then separated again on the decanter centrifuge using the same settings. The BLG l
phase was then mixed with polished water in order to make it into a slurry containing approx.
% dry—matter and having a crystallinity of BLG of approx. 80, and subsequently dried on a
pilot plant spray drier with an inlet temperature of 180 degrees C and an exit ature of 85
degrees C without any preheating. The temperature of the liquid streams until spray—drying was
—12 degrees C. The resulting powder sampled at the exit had a water content of 4.37 %
(w/w).
The crystallinity of BLG in the slurry was approximately 90%.
The inventors have also successfully separated a slurry of BLG crystals and mother liquor on a
decanter centrifuge at 350 g, 2750 RPM, 150 RPM Diff. with a 64 mil spacer and a flow rate of
75 L/h. The BLG crystal phase was uently mixed 1:2 with polished water. The BLG crys—
tal phase was then mixed with polished water in order to make it into a thinner slurry, and sub—
sequently dried on a pilot plant spray drier using the same parameters as described above.
The bulk y of the spray—dried powder was then measured ing to Example 9.3 and
compared to the bulk density of a standard WPI dried on the same equipment. The standard
WPI was found to have a bulk density (based on 625 stampings) of 0.39 g/mL which is in the
high end of the normal range for a WPI powder. However, the spray—dried BLG crystal prepara—
tion had a bulk density 0.68 g/mL, more than 75% higher than the bulk density of the standard
WPI (see e.g. Figure 23). This is truly sing and provides a number of both logistic and
application—related advantages.
W0 2018l115520
Table 12 The tration of selected components of the spray-dried BLG crystal preparation of
Example 7. BDL= below detection limit
Spray dried BLG crystal powder
Protein composition (% w/w relative to
total protein)
ALA 0.7
BLG 97.4
CMP BDL
Other components (% w/w relative to total
weight of the BLG crystal powder)
Na BDL
P BDL
water
protein concentration to.” Ace
A sample of the spray-dried BLG crystal preparation was subsequently resuspended in cold de—
mineralised water and BLG crystals were still clearly visible by microscopy. Addition of citric acid
or NaCl caused the BLG crystals to dissolve and transformed the opaque crystal suspension into
a clear liquid.
The inventors have seen tions that extended g during the drying step reduces the
amount of BLG that is in crystal form. It is therefore preferred that the heat exposure of the
BLG crystal ation is as low as possible.
Conclusion:
This e demonstrates that slurries comprising BLG crystals can be dried and that
BLG crystals are still present in the resuspended spray—dried powder if the heating during the
drying step is controlled.
The inventors furthermore found that the bulk density of a whey protein powder that ns
BLG crystals is considerably higher than that obtained by normal drying of dissolved pro—
tein streams. High density powders allows for more cost—effective packaging and logistics of the
powder as less packaging material is required per kg powder and more powder (mass) can be
transported by a given container or truck.
W0 2018!115520
The high y powder also appears to be easier to handle and less fluffy and dusty during
manufacture and use.
Example 8: Low phosphorus protein beverage
Six low phosphorus beverage samples were prepared using the purified BLG product from Ex—
ample 3 (the crystal preparation obtained from feed 3). All the dry ingredients were mixed with
demineralised water to obtain 10 kg of each sample and allowed to hydrate for 1 hour at 10
degrees C.
Table 13 Composition of the six ge samples.
Ingredient (% w/w) Beverage sample
-—--n
Dried, purified BLG from
.0 10.0 5.0 10.0 5.0 10.0
Ex. 3, feed 3
Citric acid To pH To pH To pH To pH To pH To pH
3.5 3.5 3.0 3.0 4.0 4.0
Demineralised water To To To To To To
100% 100% 100% 100% 100% 100%
The sub—samples of the six samples were taken to measure turbidity on a Turbiquant® 3000 IR
Turbidimeter and viscosity on a vicoman by . The results are shown in the table below.
Table 14 Measured ity and turbidity of the six beverage samples.
-:_—
——-_
A photo of test tubes containing sub—samples of the six low phosphorous beverage samples is
shown in Figure 25. From left to right the sub—samples were sample A, B, C, D, E, and F. The
visual inspection of the test tubes verified the turbidity measurements and documented that all
beverage samples were transparent and that ularly samples C and D (pH 3.0) were very
clear. The low viscosities demonstrate that the beverage samples were easily drinkable.
W0 2018!115520 2017/084553
All ingredients used for preparing the beverage were low in phosphorus and did not contain
unnecessary minerals. The obtained beverages therefore had a phosphorus content of approx.
45 mg P/100 g protein and generally had a very low mineral content. The siX beverages were
therefore suitable for use as protein beverages for kidney disease ts.
Example 9 — Methods of analysis
Example 9.1 Determination of lactosylated BLG vs. non—lactosylated BLG:
Quantification of the amount of lactosylated BLG and native BLG ed using LC-MS.
The analyses were performed on a 6410 Triple Quad MS from Agilent logies d with
a HP1200 series HPLC also from Agilent Technologies. For separation prior to ionization a Sym—
metry300TM C18 column (WAT106172: 5 pm solid phase particles, column dimensions 2.1x150
mm) was applied and proteins were detected at 214nm. Before the samples were analyzed they
were filtered through a 0.22 micron filter. All samples were run as duplicates.
The analyses were performed using the ing conditions:
HPLC
Buffer A: 99.9 % MilliQ—vand with 0.1 % TFA
Buffer B: 9.9 % MilliQ—vand, 90 % acetonitril, 0.1 % TFA
Flow: 0.3 mL/min
Gradient:
0—20 min: 85-60 % A and 15—40 % B
—45 min: 60—50 % A and 40—50 % B
45—55 min: 0% A and 100 % B
55—70 min 85 % A and 15 % B
Load: 40 |JL
The column temperature was set to 60 degrees C.
Mass spectroscopy:
W0 2018!115520
Ions with a m/z of 00 were ed and the resulting data was evaluated in MassHunter
Workstation Software, Ver. 80400. Using deconvolution all forms of the same species (mass)
were grouped. Masses between 18 kDa and 20 kDa were subjected to further inquiry. The intact
mass of BLG-A is 18.361 kDa and BLG—B is 18.276, a lactosylation adds 324 Da to the n
mass, by examining this mass area up to 5 lactosylations pr. n can be detected. The rela-
tive quantification is made by comparing the signal intensity for each mass, ignoring ionization
discrimination of the different species.
Example 9.2: Determination of total protein
The total protein content (true protein) of a sample is determined by:
1) Determining the total nitrogen of the sample following ISO 8968—1/2|IDF 020-1/2— Milk —
ination of nitrogen content — Part 1/2: Determination of nitrogen t using the
Kjeldahl method.
2) Determining the non—protein nitrogen of the sample following ISO 8968—4|IDF 020—4— Milk —
Determination of nitrogen content — Part 4: Determination of non—protein—nitrogen content.
3) Calculating the total amount protein as (mtotal nitrogen — mnon_protem_mtrogen)*6.38.
e 9.3: Determination of loose density and bulk density
The y of a dry powder is defined as the relation between weight and volume of the pow—
der which is analysed using a special Stampf volumeter (Le. a measuring cylinder) under speci—
fied ions. The density is typically expressed in g/ml or kg/L.
In this method a sample of dried powder is tamped in a measuring cylinder. After a specified
number of tappings the volume of the product is read and the y is calculated.
Three types of densities can be defined by this method:
- Poured density, which is the mass divided with the volume of powder after it has been
transferred to the specified measuring cylinder.
- Loose density, which is the mass divided with the volume of powder after 100 tappings
according to the specified conditions in this standard.
W0 2018!115520
- Bulk density, which is the mass divided with the volume of powder after 625 tappings ac—
cording to the specified conditions in this standard.
The method uses a l measuring cylinder, 250 ml, graduated 0—250 ml, weight 190:1:15 g
(J. Engelsmann A. G. 67059 Ludwigshafen/Rh) and a Stampf volumeter, e.g. J. Engelsmann A.
The loose density and the bulk density of the dried t are determined by the following
procedure.
eatm ent:
The sample to be measured is stored at room temperature.
The sample is then thoroughly mixed by repeatedly rotating and turning the container (avoid
crushing particles). The container is not filled more than 2/3.
Procedure:
Weigh 100.0 1 0.1 gram of powder and transfer it to the measuring cylinder. The volume V0 is
read in mi.
If 100 g powder does not fit into the cylinder, the amount should be reduced to 50 or 25 gram.
Fix the measuring cylinder to the Stampf volumeter and let it tap 100 taps. Level the surface
with the spatula and read the volume V100 in mi.
Change the number of tabs to 625 (incl. the 100 taps). After tapping level the surface and read
the volume V625 in mi.
Calculation of densities:
3O Calculate the loose and the bulk densities expressed in g/ml according to the following formula:
Bulk y = MN
where M designates d sample in grams and V designates volume after 625 tappings in
mi.
e 9.4: Determination of the water content of a powder
W0 2018!115520
The water content of a food product is determined according to ISO 5537:2004 (Dried milk —
Determination of moisture content (Reference method)). NMKL is an abbreviation for “Nordisk
Metodikkomité for Naeringsmidler”.
Example 9.5: Determination of the total amounts of calcium, magnesium, sodium, potassium,
phosphorus
The total amount of calcium, magnesium, sodium, potassium, and phosphorus are determined
using a procedure in which the samples are first decomposed using microwave digestion and
then the total amount of l(s) is determined using an ICP apparatus.
Apparatus:
The microwave is from Anton Paar and the ICP is an Optima 2000DV from Elmer Inc.
als:
1 M HN03
Yttrium in 2% HNO3
Suitable standards for calcium, magnesium, sodium, potassium, and phosphorus in 5% HN03
Pre—treatment:
Weigh out a certain amount of powder and transfer the powder to a microwave digestion tube.
Add 5 mL 1M HNO3. Digest the samples in the microwave in accordance with ave in-
structions. Place the digested tubes in a fume cupboard, remove the lid and let le fumes
evaporate.
Measurement procedure:
Transfer pre-treated sample to digitube using a known amount of Milli—Q water. Add a solution
of yttrium in 2% HNO3 to the digestion tube (about 0.25 mL per 50 mL diluted sample) and
dilute to known volume using Q water. Analyze the s on the ICP using the proce—
dure described by the manufacturer.
A blind sample is prepared by diluting a mixture of 10 mL 1M HNO3 and 0.5 mL solution of yt—
trium in 2% HN03 to a final volume of 100 mL using Milli—Q water.
At least 3 rd samples are prepared having concentrations which t the expected
sample concentrations.
W0 2018!115520
Example 9.6: Determination of the furosine—value:
The furosine value is determined as described in ard Reaction Evaluation by Furosine De—
termination During Infant Cereal Processing”, Guerra—Hernandez et al, Journal of Cereal Science
29 (1999) 171—176 and the total amount n is determined according to Example 9.2. The
furosine value is reported in the unit mg furosine per 100 g n.
e 9.7: Determination of the crystallinity of BLG in a liquid
The following method is used to determine the crystallinity of BLG in a liquid having a pH in the
range of 5—6.
a) Transfer a 10 mL sample of the liquid in question to a Maxi—Spin filter with a 0.45 micron
pore size CA membrane.
b) Immediately spin the filter at 1500 g for 5 min. g the centrifuge at 2 degrees C
c) Add 2 mL cold milliQ water (2 degrees C) to the retentate side of the spin filter and immedi—
ately, spin the filter at 1500 g for 5 min while keeping the centrifuged cooled at 2 s C,
collect the permeate (permeate A), measure the volume and determine BLG concentration via
HPLC using the method outlined in Example 9.9.
d) Add 4 mL 2M NaCl to the retentate side of the filter, agitate quickly and allow the mixture to
stand for 15 minutes at 25 s C.
e) Immediately spin the filter at 1500 g for 5 min and collect the permeate (permeate B)
f) Determine the total weight of BLG in permeate A and permeate B using the method outlined
in Example 9.9 and convert the results to total weight of BLG instead of weight percent. The
weight of BLG in permeate A is referred to as mpermeateA and the weight of BLG in permeate B is
referred to as mpermeate 3.
g) The crystallinity of the liquid with respect to BLG is determined as:
crYStallinity = mPermeate B/( mPermeate A+ mPermeate B)*100°/°
W0 15520
Example 9.8: Determination of the crystallinity of BLG in a dry powder
This method is used to determine the crystallinity of BLG in a dry powder.
a) 5.0 gram of the powder sample is mixed with 20.0 gram of cold milliQ water (2 degrees C)
and allowed to stand for 5 minute at 2 degrees C.
b) er the sample of the liquid in question to a Maxi—Spin filter with a 0.45 micron CA
membrane.
c) Immediately spin the filter at 1500 g for 5 min. keeping the centrifuge at 2 degrees C
d) Add 2 mL cold milIi-Q water (2 s C) to the ate side of the spin filter and immedi—
ately, spin the filter at 1500 g for 5 min, collect the permeate (permeate A), measure the vol—
ume and determine BLG concentration via HPLC using the method outlined in Example 9.9. and
convert the results to total weight of BLG d of weight percent. The weight of BLG in per—
meate A is referred to as mpermeateA
f) The crystallinity of BLG in the powder is then calculated using the following formula:
crystallinity = mBLGtotaLTmpermeateA
* 100%
mBLG total
where mBLGtotal is the total amount of BLG in the powder sample of step a).
If the total amount of BLG of powder sample is unknown, this may be ined by suspend—
ing another 5 g powder sample (from the same powder source) in 20.0 gram of milliQ water,
adjusting the pH to 7.0 by addition of aqueous NaOH, allowing the e to stand for 1 hour
at 25 degrees C under stirring, and finally determining the total amount of BLG of the powder
sample using Example 9.9.
Example 9.9: Determination of the total amount of BLG, ALA, and CMP in an aqueous liquid
The content of alpha—Iactalbumin, beta—Iactoglobulin and CMP was analyzed by HPLC analysis at
0.4mL/min. 25 microL filtered sample is injected onto 2 TSngl3000PWX| (7.8 mm 30 cm, To-
sohass, Japan) columns connected in series with attached precolumn Ple (6 mm x 4 cm, To—
sohass, Japan) equilibrated in the eluent (consisting of 4659 MiIIiQ water, 417,3 9 acetonitrile
and 1mL triflouroacetic acid) and using a UV detector at 210nm.
Quantitative ination of the ts of native alpha—Iactalbumin (Camha), beta—
Iactoglobulin (Cbeta), and caseinomacropeptide (CCMP) was performed by comparing the peak
areas obtained for the corresponding standard proteins with those of the samples.
W0 2018!115520
The total amount of additional protein (non—BLG protein) was determined by subtracting the
amount of BLG from the amount of total protein (determined according to Example 9.2)
Example 9.10: Determination of UF permeate conductivity
mL of sample is transferred to an Amicon Ultra—15 Centrifugal Filter Units with a 3 kDa cut
off (3000 NMWL) and centrifugated at 4000 g for 20-30 minutes or until a sufficient volume of
UF permeate for measuring conductivity is accumulated in the bottom part of the filter units.
The tivity is measured immediately after centrifugation. The sample handling and cen—
ation is performed at the temperature of the source of the sample.
Example 9.11: Determination of the degree of protein denaturation of a whey protein composi—
tion
Denatured whey protein is known to have a lower solubility at pH 4.6 than at pH 7.0 and the
degree of denaturation of a whey protein composition is determined by measuring the amount
of soluble n at pH 4.6 relative to the total amount of protein at pH 7.0.
More specifically, the whey protein composition to be analysed (e.g. a powder or an aqueous
solution) is converted to:
— a first aqueous solution containing 5.0% (w/w) total protein and having a pH of 7.0, and
— a second aqueous solution containing 5.0% (w/w) total protein and having a pH of 4.6.
pH adjustments are made using 3% (w/w) NaOH (aq) or 5% (w/w) HCI (aq).
The total protein content (PpH 7_0) of the first aqueous solution is determined according to exam—
ple 9.2.
The second aqueous solution is stored for 2 h at room ature and uently centri—
fuged at 3000 g for 5 minutes. A sample of the supernatant is red and analysed accord—
ing to Example 9.2 to determine total n (SpH 4.6).
The degree of protein denaturation, D, of the whey protein composition is calculated as:
D = ((PpH 7.0—SpH 4.6)/ PpH 7.o)*100%
e 9.12: Detection of dried BLG crystals in a powder
W0 2018!115520
The presence of dried BLG crystals in a powder can be identified the following way:
A sample of the powder to be analysed is resuspended and gently mixed in demineralised water
having a temperature of 4 degrees C in a weight ratio of 2 parts water to 1 part , and
allowed to ate for 1 hour at 4 degrees C.
The rehydrated sample is ted by microscopy to identify presence of crystals, preferably
using plan polarized light to detect birefringence.
Crystal—like matter is separated and subjected to x—ray llography in order verify the exist—
ence of crystal structure, and preferably also verifying that the crystal lattice (space group and
unit cell dimensions) corresponds to those of a BLG crystal.
The chemical composition of the separated crystal-like matter is analysed to verify that its sol-
ids primarily consists of BLG.
Example 10: Crystallisation by UF-based dynamic cross flow filtration
Feed for the crystallization tank was prepared as described in Example 1 with the exception that
diafiltration was carried out at pH 5.92 and the end TS was 20%.
After the feed was ioned (the feed ition can be seen in Table 15) it was trans—
ferred to a 300L crystallization tank and the pH was initially adjusted to pH 5.80 and the tem—
perature was kept as 10—12 degrees C. After pH adjustment, seeding material was added which
had been produced in the same fashion as described in Example 1, but originating from a non-
spontaneous crystallization production. The feed was seeded with seeding material to a concen-
tration of 0.5 g seeding material per liter feed. After seeding, the ature on the cooling
mantle was set to 5 degrees C, pH was slowly adjusted to 5.50, and the mixture was left to
3O crystallize for approximately an hour, after which the DCF (Dynamic Crossflow Filtration) unit
was connected to the crystallization tank as shown in figure 26. The DCF unit was fitted with
Kerafol ceramic membranes with a pore size of 500 nm, the TMP (Trans ne Pressure)
was set to 0.4 bar and the rotational speed of the membrane was 32 Hz.
Retentate from the DCF was returned to the crystallization tank, while the permeate was used
as feed in a UF (ultrafiltration) unit ed with a Koch HFK—328 type membrane with a 46
mil spacer. In the UF unit, temperatures were allowed to rise up to but not above 12 degrees C.
The amount of diafiltration water added was adjusted so that the retentate coming out of the
UF, going back to the crystallization tank, was about 21% TS, while ls were removed
from the mother liquor (ML).
Diafiltration on the ML continued until the difference in conductivity between the permeate and
the diafiltration water was below 50 /cm. At this point the amount of diafiltration water
was adjusted so that the retentate was around 30% TS. The amount of TS in the ML decreases
when BLG is removed as cn/stals; this continuous l of excess water and minerals makes
it possible to drive the l yield, as it seems that the concentration of other proteins during
BLG crystallization has an d effect, if any, on the solubility of BLG in the ranges that have
been explored.
The composition of the ML permeate from the DCF can be seen in Table 16. The initial 300L of
feed had been reduced to around 100L of ML. Based on mass conservation the relative yield of
BLG was calculated to 92 %.
Table 15 Selected components of the feed used in Example 10.
Feed standardized to 95% T5
., n composition (% w/w relative to
total protein)
TALA 22.9
.....
BLG 50.2
:WCMP and other prote— 26.5
WOther components (% w/w relative to total
weight of the standardized feed)
"Ca 0.387
k ,0350
Mg .__________,_%,,,0'058
Na ................ . .0245......
P 0.2.1.0.............
"Fat ____________________________________________________________BDL _________________________
protein 90
Table 16 Protein composition of the final mother liquor obtained in Example 10.
f’ Finél‘MLéEéHdardiiéd E0 95% ts““““““““““
Protein com pOSition (0/6 W/wurelative to."
total protein)
W0 2018!115520
ALA 42.9
BLG 6.8
WCMP and other prote— 50.3
Conclusion:
By continuously removing excess minerals and water from the matrix where the BLG crystalli—
zation takes place, the BLG yield can be significantly improved and the process can be carried
out at low temperatures.
Example 11: Degree of protein denaturation of different whey protein ts
The degree of protein denaturation of a commercial t and four edible BLG compositions
of the ion were compared. The samples are described below.
Samples
A: BiPro (Commercially available WPI; Davisco, USA)
B: BLG crystal slurry as is — no drying (invention)
C: BLG crystal slurry freeze dried (invention)
D: BLG crystals redissolved (pH 7) and freeze—dried
E: BLG crystal slurry spray dried (invention)
Samples B—E were ed the following way:
A crystal slurry was prepared as described in Example 12 and separated as described in Exam—
ple 7. Some the separated BLG slurry was taken out and split into four portions.
Sample B: The first portion of the separated BLG crystal slurry was re—dissolved without any
drying by adjusting the pH of the BLG crystal slurry to 7.01 using a 3% NaOH; and sample was
then diluted to Bx 6 in order to make an approximately 5% n solution.
Sample C: The second portion of the separated BLG crystal slurry was freeze—dried. The powder
was then resuspended in polished water, the pH was adjusted to 7.09 using a 3% NaOH, and
the sample was then diluted to Brix 6 in order to make an imately 5% protein solution.
Sample D: The third portion of the ted BLG crystal slurry was re—dissolved by adjusting
the pH to 7.0 using a 3% NaOH, then freeze dried. The freeze dried powder was then re—
W0 2018!115520
suspended in polished water, and the pH was measured to be 7.07. The sample was then dilut—
ed to Brix 6 in order to make an approximately 5% protein solution.
Sample E: The fourth portion of the separated BLG l slurry was d and spray dried as
described in Example 7. The powder was then re—suspended in polished water and the pH was
adjusted to 7.04 using a 3% NaOH. The sample was then diluted to Brix 6 in order to make an
approximately 5% protein solution.
The degree of protein denaturation of each sample was determined according to Example 9.11
and the results are presented in Table 17.
Table 17 Comparing the degree of protein denaturation of a commercially available WPI t
(Bipro) with 4 BLG products of the invention.
Total pro-
Total concentra- Degree of pro—
tein
tion tein
Sample contclirrl]tra- of soluble protein denaturation
atpH4.6 ()/oD
at H7
A: BiPro rcially available WPI) 4. 54 11. 15
B: BLG crystal slurry as is (no drying 4.56 1.30
C: BLG crystal slurry freezwe dried 4.69 1.05
D: BLG ls redissolved (pH 7) and freeze— 4.69 1.05
drled
E: BLG crystal slurry spray dried 4.71 0.84
Conclusion:
less of the drying method, the edible BLG compositions of the invention have a surpris—
ingly low degree of denatured protein; only a tenth of what can be found in the commercially
available WPI used for comparison. It is particularly surprising that the spray—dried BLG crystal
slurry product still has the lowest degree of denaturation of all products.
Example 12: Crystal separation by dynamic cross-flow filtration
Lactose—depleted UF retentate derived from sweet whey from a standard cheese production
process, ed through a 1.2 micron filter, was used as feed for the crystallization process.
The sweet whey feed was conditioned on an ultrafiltration setup using a Koch 8 type
membrane with a 46 mil spacer, a feed pressure of 1.5—3.0 bar, using a feed concentration of
% TS (total solids) i5, and ed water (water filtered by reverse osmosis to obtain a
tivity of at most 0.05 mS/cm) as diafiltration medium. The ature of the feed and
retentate during ultrafiltration was approx. 12 degrees C. The pH was then adjusted by adding
HCI to obtain a pH of approx. 5.60. Diafiltration continued until the conductivity of the retentate
W0 2018!115520 2017/084553
was below 1.30 mS/cm. The feed was then heated to 25 degrees C before the retentate was
concentrated to approx. 27% TS (approx. 21% total protein ve to the total weigh of the
concentrated retentate). The permeate conductivity was 0.33 mS/cm at the end of concentra—
tion. A sample of the concentrated retentate was centrifuged at 3000 g for 5 minutes but no
visible pellet was formed.
The trated retentate was transferred to a 300L crystallization tank where it was cooled to
about 6 degrees C and kept at this temperature overnight with gentle stirring. The next morn—
ing, the retentate had crystallized. The mother liquor and the ls were separated by cen—
trifugation 3000 g for 5 minutes, and samples of the supernatant and pellet were taken for
HPLC analysis. The yield of BLG from this process was calculated to 67%.
The crystal slurry from the 300 L tank was used for a feed in and Andritz DCF 1528 system
using one disk membrane with a pore size of 500nm. The filtration was run at 8 degrees C, ro-
tational speed was 32Hz, and the transmembrane pressure was 0.4 bar. The system works as a
dead end filtration where retentate is built up in the filtration chamber, unlike a larger unit
where the retentate would be continuously removed. The filtration was run in a stable manner
for just over 40 minutes at which point the solids which had built up in the filtration chamber
started to influence the tion.
The amount of crystal mass increased significantly during the DFC operation.
Conclusion.
The DCF provides a stable and efficient means for separating the crystals from the ML. If need—
ed g liquid could be added to the DCF.
Example 13: Crystal tion using a filtration centrifuge
Using the same feed and the same crystallization process as in e 12, separation was
tested on a Filtration fuge HZ 25/0.1 fitted with a filter cloth with a pore size of around 20
micro meters.
Test 1: 4 L of the feed was fed in to the filter centrifuge which was run at 60 9. After all feed
had been added, the centrifuge was accelerated to 250 g for drying the filter cake. The cake
contained 47.6% TS; the composition of the cake is shown in Table 18.
After cleaning, the centrifuge was fed with 7 L of the same feed as bed above at 60 g. The
centrifuge was then accelerated to 250 g for dewatering for approximately 5 minutes, before it
again was decelerated to 60 g, and 0.25 L of polished water was added for wash. After the
washing water had been added, the centrifuge was again accelerated to 250 g for dewatering.
W0 2018!115520
The TS of the cake was measured to be 47%. The cake is shown in figure 27.A. The composi—
tion of the cake, ML fraction, and the washing liquid after wash are shown in Table 18. After the
cake had been dewatered, it was attempted to peel it off the sides of the centrifuge; the top
layer did smolder and fall out through the intended tube as seen in figure 27.C, but the under—
lying layer was too moist and sticky to peel properly as seen in figure 27.8.
Table 18 tration of seiected components of the compositons provided in Example 13.
Crystalli— ML after Filter cake, ML after Filter cake, g
zation feed centrifu— no washing centrifu— with water after
gation gation washing wash
(Test 1) (Test 1) (Test 2) (Test 2) (Test 2)
Proteins1 :
ALA 1.50
BLG 12.4
CMP 3.56
Other compo-
nentsz):
1) Protein composition % (w/w) relative to the weight of the solution
2) Concentration of other selected components (% w/w relative to total weight of composition
standardized to 95% total solids)
Conclusion:
Filter fuges provide an interesting option for ing a BLG cake that is so pure that ALA
and CMP are below the level required for quantification even without washing. By applying even
a small volume of washing medium to the filter cake the mineral content in the cake can be
lowered even further, as seen by the protein composition of the washing water in Table 18. The
content of non-BLG protein of the cake is also lowered by g as one can see from the
used washing water. The used g water contains a ratio between ALA:BLG that is larger
than the ratio in the filter cake. This indicates that the g step has a larger tendency to
remove ALA (and probably other non—BLG proteins) than BLG.
The filter cakes that were produced here were not peelable but still permeable. This enables the
option of adding a dry gas at a given temperature in order to lower the moister content of the
W0 2018!115520 2017/084553
filter cake to a degree where it is peelable, like the top layer. Alternatively the filter cake could
be solved inside the centrifuge by adding the right amount of acid, base, or salt in an
aqueous solution in a siphon centrifuge style setup.
e 14: Impact of mineral composition of the whey protein solution
The impact of the molar ratio between alent and divalent metal-cations on the yield of
BLG was investigated in this example.
Two samples were compared:
Sample A: Having an overweight of Na+ (source: NaZSO4)
Sample B: Having an overweight of Ca2+ (source: CaSO4)
The same type of raw material as used in e 1 was adjusted with 2.5% sulfuric acid. The
pH of the samples was adjusted to around pH 5.4; the precise pH is reported in Table 20. The
original volume of each sample was 250 mL. The two samples were dialysed in another 24 L
container against approximately 24 L of cold polished water. For all dialysis processes, dialysis
tube OrDiaI D-Clean MWCO 3500 (item number 63034405) was used. The containers were con—
tinuously stirred during the dialysis processes, and the dialysis took place in a cooler at 4 de—
grees C. The first dialysis took place over night.
To remove excess ions after the first is, the dialysis bags were transferred to a container
containing 2 L of salt solution. The concentrations were as follows:
Sample A: NaZSO4 (Sodium sulfate) 0.059 M,
Sample B: CaSO4 (calcium sulfate) 0.059 M.
The first salt dialysis took place over night. The conductivity, pH and Brix after the first salt
dialysis are reported in Table 20. The salt solutions where changed to fresh ones and the dialy—
sis continued over the weekend.
After the second salt dialysis, the tubes where transferred to a 24 L container filled with ap—
proximately 24 L of cold polished water and dialysed overnight to remove excess ions before
crystallization.
After the last dialysis step, the protein concentration was a bit lower than what was preferred.
The samples were ore concentrated on a Pellicon XL UF lab setup using a 10kDa cut off
ne and a peristaltic pump running at 75 mL/h. The l content of the samples
along with the raw material are shown in Table 19.
The samples were then seeded with 0.5 g/L of the seeding material previously described, and
left to crystallize at 4 degrees C overnight. Then next day, crystal precipitate was visible in all
samples. HPLC samples of each of the samples were prepared by centrifuging each sample at
30009 for 5 minutes, followed by analyzing a sample of the atant. The results are shown
in Table 21.
Table 19 Concentrations of selected mineral components in the raw material and samples A and B of
Example 14.
Component ? Raw material i Sample A 3 Sample A ? Sample B Sample B
before cryst. change” before cryst.
. i ‘y l)
(% W/W) (% W/W) (°/°) (°/0 W/W) (%)
Calcium 0.45 0.13 -71 0.82 82
Chloride 0.21 Not tested V; Not tested ; Not tested Vi Not tested
Potassium 0.60 0.04 _93 0.06 _90
[Magnesium V
0.08 0.02 -75 0.02 —75
..... .. ,,
Sodium 0.14 0.59 321 0.08 _43
VVVVPhosphorus V V
0.22 0.21 -5 0.24 9
VVWProtein W8W6.9 2 87.8 1 86.2 -1
Ml) The change isrelative to the concentration of the—given componentsin the
raw al
Table 20 pH, conductivity and degrees Brix at various stages during the preparation of s A
and B.
pH ; cond. (mS/cm) brix(° )
21.9
: . 15.4
After second salt dialysis 5.51 H V
576 12.3
A After l of excess ion via dialy— 5.48“ 0.883 9.5
. sis
fterprotein concentratIon via lab UF 5.48 I; 1.622 ' 16.4
Final pr-ladjustmentVVVV 5.482
pH adjustment? 541 V V
352 21.9
_After fir
. salt dialysisw . ,
After secondsalt dlalYSISVV V V
. .. ,. H
B After removal of eXceSS ion via dIaly—VV
B l After proteIn tratIon via labUF ? 5.32 0.891 11.9
__ ,, _ ,,,,,,
B Final pH:adjustment“ 15-42
Sample BLG(%w/w)
A (high Na+) — whey protein solution with BLG crystals E 6.47
fore separation
A (high Na+) — mother liquor after separation of crystals 3.94
B (high Ca2+) — whey protein solution with BLG crystals 3.56
' before separation
B (high Ca2+) — mother liquor after separation of crystals 2.22
Conclusion:
Table 21 documents that a smaller residual amount of BLG is left in the mother liquor (and a
higher yield of separated BLG crystals is obtained) if a high molar ratio between monovalent
and divalent cations is avoided. The molar ratio between monovalent and nt cations, and
in ce Na+K vs. Ca+Mg, can be controlled to improve the yield of BLG of the present
method.
Claims (42)
1. A method of preparing an edible composition comprising beta-lactoglobulin (BLG) in crystal— lised and/or isolated form, the method comprising the steps of a) ing a whey n solution comprising BLG and at least one additional whey pro— tein, said whey protein solution is: — supersaturated with respect to BLG and has a pH in the range of 5-6, — comprises BLG in an amount of at most 90% (w/w), b) crystallising BLG in the supersaturated whey protein solution, preferably in salting—in mode, and c) optionally, separating BLG crystals from the remaining whey protein solution.
2. The method according to claim 1 furthermore comprising a step d) of washing BLG crystals, e.g. the separated ls obtained from step c). 20
3. The method according to claim 1 or 2 furthermore comprising a step e) of re—crystallising BLG crystals, e.g. the BLG crystals obtained from step c) or d).
4. The method according to any of the preceding , furthermore comprising a step f) of drying a BLG—containing composition derived from step b), c), d), or e).
5. The method according to any of the preceding claims, wherein the whey n solution of step a) ses at least 5% (w/w) ALA relative to the total amount of protein.
6. The method according to any of the preceding claims, wherein the whey protein solution of 3O step a) comprises at least 15% (w/w) additional whey protein relative to the total amount of protein.
7. The method according to any of the preceding claims, wherein the whey protein on of step a) comprises at least 1% (w/w) BLG ve to the total amount of protein.
8. The method according to any of the preceding claims, wherein the whey protein solution of step a) comprises at least 0.4% (w/w) BLG relative to the weight of the whey protein solution. RECTIFIED SHEET (RULE 91) ISA/EP
9. The method according to any of the preceding claims, n the whey protein solution comprises a milk serum protein trate, a whey protein concentrate, milk serum protein e, and/or whey protein isolate.
10. The method according to any of the preceding claims, wherein the ratio between the con- ductivity and the total amount of protein of the whey protein solution is at most 0.3.
11. The method according to any of the preceding claims, n the UF permeate conductivi— ty of the whey protein solution is at most 7 mS/cm.
12. The method ing to any of the preceding claims, wherein the supersaturated whey protein solution is prepared by subjecting a whey protein feed to one or more of the following adjustments: - Adjusting the pH, 15 - Reducing the conductivity — Reducing the temperature - sing the protein concentration, and — Adding an agent that reduces the water activity. 20
13. The method according to any of the preceding claims, wherein the preparation of the whey protein solution involves adjusting the pH of the whey n feed.
14. The method according to any of the preceding claims, wherein the preparation of the whey protein solution involves reducing the conductivity of the whey protein feed.
15. The method according to any of the preceding claims, wherein the preparation of the whey protein solution involves reducing the temperature of the whey protein feed.
16. The method according to any of the ing claims, wherein the preparation of the whey 30 protein on es increasing the total protein concentration of the whey protein feed.
17. The method according to any of the preceding claims, wherein the crystallisation of BLG of step b) involves one or more of the following: — g for crystallisation to take place, 35 - Addition of crystallisation seeds, — Increasing the degrees of degree of supersaturation of BLG even further, and/or — Mechanical stimulation. RECTIFIED SHEET (RULE 91) ISA/EP
18. The method according to any of the claims 1-17, wherein step c) comprises separating the BLG crystals to a solids content of at least 30% (w/w), preferably at least 40% (w/w) and even more preferably at least 50% (w/w).
19. The method according to any of the claims 2-19, wherein the washing in step d) es contacting the separated BLG crystals with a washing liquid without completely dissolving the BLG ls and uently separating the remaining BLG crystals from the washing liquid.
20. The method according to claim 19 wherein the washing of step d) dissolves at most 80% 10 (w/w) of the initial amount of BLG crystals, preferably at most 50% (w/w), and even more preferably at most 20% (w/w) of the initial amount of BLG ls.
21. The method according to any of the claims 3-20 wherein the recrystallization step involves: - dissolving the separated BLG ls in a recrystallization liquid, 15 - adjusting the recrystallization liquid to obtain supersaturation with respect to BLG, — crystallising BLG in the supersaturated, adjusted recrystallization liquid, and — separating BLG crystals from the remaining adjusted recrystallization liquid.
22. The method according to any of the claims 3-21, wherein BLG crystals of step d) are recrys— 20 tallized at least 2 times
23. The method according to any of the claims 4—22 wherein the drying step involves one or more of spray drying, freeze drying, lash drier, rotary drying, and/or fluid bed drying. 25
24. An edible BLG composition, said composition is obtainable by one or more processes ac— cording to any of the claims 1—23.
25. An edible BLG ition comprising at least 90% (w/w) BLG relative to total solids. 30
26. The edible BLG composition according to claim 25, and having a crystallinity of BLG of at least 10%.
27. An edible BLG composition ing to any of the claims 24-26 comprising at most 90% (w/w) BLG relative to the total amount of protein, and having a crystallinity of BLG of at least 35 10%.
28. The edible BLG composition according to any of the claims 24 to 27, wherein the composi— tion is a dry composition. RECTIFIED SHEET (RULE 91) lSA/EP
29. The dry BLG composition according to claim 28, in the form of a powder having a bulk den— sity of at least 0.4 g/mL, preferably a spray—dried powder.
30. The dry BLG composition according to claim 28 or 29 comprising - at least 20% (w/w) BLG relative to the total amount of protein, and — a crystallinity of BLG of at least 10%.
31. The edible BLG composition ing to any of the claims 24 to 27, wherein the composi— tion is a liquid composition.
32. The edible BLG composition according to any of the claims 24 to 31, whererin the i— tion is a low mineral composition.
33. The edible BLG ition according to any of the claims 24 to 32, whererin the i- 15 tion is a low phosphorus composition.
34. Use of an edible BLG composition according to any of the claims 24—33 as a food ingredient.
35. Use of a low orus, edible BLG composition according to any of the claims 24—33 as a 20 food ingredient in the production of a low orus food product.
36. A food product comprising an edible BLG composition according to any of the claims 24—33 and at least an additional ingredient, such as e.g. a source of fat and/or carbohydrate. 25
37. The food product according to claim 36 which is a dry food product comprising ydrate and protein, said dry food product sing at least 1% (w/w) BLG, wherein: i) the BLG has a crystallinity of at least 10%, and/or ii) at least 90% (w/w) of the total amount of protein is comprised by BLG, 30
38. The food product according to any of the claims 36-37, which is a low phosphorus food product comprising at most 80 mg phosphorus per 100 g protein.
39. The food product according to any of the claims 36—38, which is a dairy product, a candy, a beverage, a protein bar, or an enteral nutritional composition.
40. The food product according to any of the claims 36—39, in the form of a beverage: — comprising the edible product according to any of the claims 24-33 to provide at total amount of BLG of at least 1% (w/w), - a sweetener, RECTIFIED SHEET (RULE 91) ISA/EP — at least one food acid, — having a pH in the range of 2.5-4.0, and — at most 80 mg phosphorus per 100 g protein.
41. An isolated BLG crystal having an orthorhombic space group P 21 21 21 and the unit cell di- mensions 8 (i5%) A, b = 68.68 (i5%) A, and c = 156.65 (:l:5%) A; and having the unit cell integral angles o=90°, B=90°, and v=90°.
42. The isolated BLG crystal according to claim 41 comprising a least 20%(w/w) BLG and at 10 most about 80% (w/w) water. RECTIFIED SHEET (RULE 91) ISA/EP WO 15520
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16206861.3 | 2016-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ755082A true NZ755082A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017380258B2 (en) | Production of novel beta-lactoglobulin preparations and related methods, uses, and food products | |
JP7467364B2 (en) | Process for producing beta-lactoglobulin isolate and related methods and uses | |
JP7431181B2 (en) | Novel methods for preparing alpha-lactalbumin enriched compositions, related products and use in infant formula, etc. | |
NZ755082A (en) | Production of novel beta-lactoglobulin preparations and related methods, uses, and food products | |
EA040134B1 (en) | METHOD FOR OBTAINING FOOD COMPOSITION CONTAINING BETA-LACTOGLOBULIN IN CRYSTALIZED FORM | |
US20240114919A1 (en) | Crystallisation of beta-lactoglobulin using multiple protein feeds | |
JP2002315506A (en) | Method for producing whey mother liquid powder |